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Abstract 
Name: Muhammad Nazhif Bin Zaini 
Title: Endogenous Reporter Systems for High-Throughput Functional 
Screening in Clear Cell Renal Cell Carcinoma 
Tissue-specific transcriptional programs define cancer phenotypes. However, 
the molecular mechanism behind the transcriptional specificity is mostly unknown, 
hindering the development of therapeutic approaches. In clear cell renal cell 
carcinoma (ccRCC), loss of von Hippel-Lindau tumour suppressor (VHL), seen in 90% 
of ccRCCs, leads to the stabilization of hypoxia inducible factor HIF2A and aberrant 
expression of its downstream targets such as the chemokine receptor CXCR4. 
Activation of HIF2A has been shown to be important for ccRCC tumour initiation and 
early progression and the expression of CXCR4 promotes metastatic progression in 
ccRCC. It is unclear, however, how VHL loss results in ccRCC specific tumorigenesis, 
one possibility being that HIF2A mRNA is expressed at a high enough level only in the 
cell lineage that eventually forms ccRCCs. 
 To investigate this hypothesis, novel experimental reporter systems were 
developed to dissect the mechanisms regulating HIF2A mRNA expression and 
activity. These endogenous HIF2A and CXCR4 reporter systems express an mCherry 
fluorescent marker at the 3’ end of their respective locus. Homology-directed repair 
(HDR)- and non-homologous end joining (NHEJ)-based CRISPR-Cas9 knock-in 
strategies were utilized for the development of these systems that involve homology-
dependent and minicircle-aided integration, respectively. These reporters were 
integrated precisely in the genome as evidenced by sequencing. The efficiency of 
these systems at detecting fluctuations in the mRNA expression of the associated 
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endogenous gene was validated by analysing mCherry fluorescence in cells with 
either CRISPRi-based HIF2A inactivation or VHL-reintroduction. Moreover, these 
reporters also proved feasible for genetic screens as shown from an sgRNA 
enrichment experiment that highlighted sgRNAs targeting regulatory factors within a 
specific population of cells.  
 These reporter systems were applied with focused CRISPR-Cas9 libraries 
targeting transcription factors (TF) and chromatin regulators for high-throughput 
screenings. Our screening data was analysed through a permutation analysis to 
remove false positive hits. In the HIF2A reporter screen with the TF library and the 
chromatin library, HIF2A was the sole significant hit, suggesting redundancy within the 
HIF2A gene regulatory machinery. In sum, I have developed and technically validated 
novel reporter systems that could aid in the systematic interrogation of cancer 
transcriptional dependencies, hence paving the way for novel therapeutic approaches.  
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Abstract 
Tissue-specific transcriptional programs define cancer phenotypes. However, 
the molecular mechanism behind the transcriptional specificity is mostly unknown, 
hindering the development of therapeutic approaches. In clear cell renal cell 
carcinoma (ccRCC), loss of von Hippel-Lindau tumour suppressor (VHL), seen in 90% 
of ccRCCs, leads to the stabilization of hypoxia inducible factor HIF2A and aberrant 
expression of its downstream targets such as the chemokine receptor CXCR4. 
Activation of HIF2A has been shown to be important for ccRCC tumour initiation and 
early progression and the expression of CXCR4 promotes metastatic progression in 
ccRCC. It is unclear, however, how VHL loss results in ccRCC specific tumorigenesis, 
one possibility being that HIF2A mRNA is expressed at a high enough level only in the 
cell lineage that eventually forms ccRCCs. 
 To investigate this hypothesis, novel experimental reporter systems were 
developed to dissect the mechanisms regulating HIF2A mRNA expression and 
activity. These endogenous HIF2A and CXCR4 reporter systems express an mCherry 
fluorescent marker at the 3’ end of their respective locus. Homology-directed repair 
(HDR)- and non-homologous end joining (NHEJ)-based CRISPR-Cas9 knock-in 
strategies were utilized for the development of these systems that involve homology-
dependent and minicircle-aided integration, respectively. These reporters were 
integrated precisely in the genome as evidenced by sequencing. The efficiency of 
these systems at detecting fluctuations in the mRNA expression of the associated 
endogenous gene was validated by analysing mCherry fluorescence in cells with 
either CRISPRi-based HIF2A inactivation or VHL-reintroduction. Moreover, these 
reporters also proved feasible for genetic screens as shown from an sgRNA 
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enrichment experiment that highlighted sgRNAs targeting regulatory factors within a 
specific population of cells.  
 These reporter systems were applied with focused CRISPR-Cas9 libraries 
targeting transcription factors (TF) and chromatin regulators for high-throughput 
screenings. Our screening data was analysed through a permutation analysis to 
remove false positive hits. In the HIF2A reporter screen with the TF library and the 
chromatin library, HIF2A was the sole significant hit, suggesting redundancy within the 
HIF2A gene regulatory machinery. In sum, I have developed and technically validated 
novel reporter systems that could aid in the systematic interrogation of cancer 
transcriptional dependencies, hence paving the way for novel therapeutic approaches.  
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Chapter 1: Introduction 
1.1 What is cancer? 
Cancer is a group of diseases that comprises more than 200 different types, 
each of which is classified by the initial type of cell affected. These altered cells grow 
uncontrollably and interfere with the normal physiological functions of the tissue 
system where they reside. Cancerous cells can also migrate from their tissue of origin 
to other parts of the body where they grow and invade healthy tissues. This invasive 
process is known as cancer metastasis. Most cancer-associated deaths involve 
metastatic forms of cancer as treatment becomes more complicated1.  
Cancer is a major health problem worldwide with more than 18 million new 
cases in 2018 along with an estimate of more than 9 million cancer-related deaths2. 
This disease is the second leading cause of death in the United States. The American 
Cancer Society reported that overall cancer death rate dropped continuously from 
1991 to 2015 by a total of 26%. However, 1,735,350 new cancer cases and 609,640 
cancer deaths are projected to occur in the United States in 20183.  Of these projected 
new cancer cases, prostate and breast cancer are the most prominent in males and 
females, respectively, with lung cancer coming a close second in both sexes.  In 
contrast, lung cancer deaths are estimated to be the highest in both males and 
females3. Cancer Research UK has documented 359,960 new cases of cancer in the 
UK in 2015 of which more than half is attributed to either breast, prostate, lung or 
bowel cancer. Incidence rates for all cancers combined have increased by 13% in the 
UK since the early 1990s4. Breast cancer is the most common cancer in the UK with 
almost a sixth of all cases in males and females combined. This is followed by prostate, 
lung and bowel cancer5. In 2016, more than 160,000 deaths from cancer was 
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documented and this accounts around 28% of all deaths in the UK6. The survival rate 
for all cancers combined in England and Wales during 2010-2011 showed 46% of men 
and 54% of women are predicted to survive their cancer for ten years or more7. In the 
US, approximately 15.5 million cancer survivors were recorded in 20168.  
 
1.1.1 Hallmarks of cancer progression 
 The biology of cancer is founded by distinctive and complementary capabilities 
that enable tumour growth and metastatic dissemination. These are known as the 
hallmarks of cancer that consist of six biological capabilities acquired during the 
multistep development of human tumours to overcome the defensive mechanisms 
against aberrations put forward by the human body (Figure 1). This include sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, inducing 
Figure 1: Six core hallmarks of cancer. Source: Hanahan D, Weinberg RA. Hallmarks 
of cancer: The next generation. Vol. 144, Cell. 2011. p. 646–74. 
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angiogenesis, enabling replicative immortality and activating invasion and metastasis. 
Enabling characteristics crucial to the acquisition of the six hallmarks of cancer are 
genomic instability and mutations9. Experimental evidence of each hallmark and the 
enabling characteristic is discussed further below.  
 
1.1.1.1 Sustaining proliferative signalling 
 For cancer cells to form tumours, they would have to sustain chronic 
proliferation as a major prerequisite. This marks the first hallmark trait of cancer and it 
is achieved through the deregulation of growth-promoting signals. In normal tissues 
these signals are tightly controlled to instruct proper entry and progression through 
cell growth and cell division cycles. This process is governed by growth factors that 
are polypeptides bound to transmembrane receptors harbouring kinase activity, which 
stimulate specific combinations of intracellular signalling pathways9. In cancer, 
hijacking of these normal mitogenic signalling propels cell proliferation through a 
number of cell-biological properties that puts them in favour of survival10,11.  
 One of the ways cancer cells sustain their proliferative prowess is by producing 
growth factors themselves along with the expression of their respective receptors12. A 
well-known example can be seen involving the epidermal growth factor (EGF) family. 
All EGF family members bind to receptor tyrosine kinases (EGFR (ERBB1), ERBB2-
4). Similar to other tyrosine kinases, each receptor molecule consist of an extracellular 
domain to allow ligand binding, a single transmembrane part and an intracellular 
protein kinase domain11. Autocrine signalling loops involving an EGF-like ligand has 
been observed along with mutation, amplification, or dysregulation of at least one of 
the ERBB family members in >20% of solid tumours. EGFR gene amplification is 
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characteristic in around 50% of glial tumours13. At least 10% of non-small cell lung 
cancer patients harbour stimulatory EGFR mutations14. Moreover, amplification of the 
ERBB2 gene is a feature of 20-25% of metastatic breast cancers15 as well as being 
observed in ovarian cancer, stomach cancer, and aggressive forms of uterine 
cancer11. Furthermore, cancer cells could also send signals to stimulate normal cells 
within the surrounding tumour-associated stroma to supply growth factors for their own 
benefit16. 
 Cancer cells also utilize nutrients through the autophagy machinery to maintain 
a hyperproliferative state. This is an intracellular nutrient scavenging pathway whereby 
cells break down cellular organelles, such as ribosomes and mitochondria, allowing 
the resulting catabolites to be recycled and thus used for biosynthesis and energy 
metabolism17. The basal autophagy levels can be higher in tumour cells when 
compared to normal cells and tumour cells constitutively depend on autophagy for 
survival. Hypoxic tumour regions also induce autophagy and confers a survival 
advantage. Furthermore, genetically engineered mouse models have shown the 
importance of autophagy for cancer progression17.  
 
1.1.1.2 Evading growth suppressors 
 To complement the positively acting growth-stimulatory signals, cancer cells 
evade powerful cellular programs that negatively regulate cell proliferation that are 
usually governed by tumour suppressor genes. Two such suppressors encode the RB 
(retinoblastoma-associated) and TP53 proteins where they control the proliferation of 
cells as well as the activation of cell cycle arrest9.  
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 The discovery of the RB gene as the first tumour suppressor focused on its role 
as a central regulator of cell cycle progression18. In addition to serving as a G1 phase 
checkpoint by inhibiting the activity of E2F transcription factors and arresting cell cycle 
progression, RB is also involved in the control of cellular differentiation and 
maintenance of permanent cell cycle arrest19,20. It was also shown that RB controls 
the G1 - S phase transition by interacting with the anaphase-promoting 
complex/cyclosome (APC/C) that leads to the control of p27 cell cycle inhibitor 
stability21. Loss of RB through the expression of the E7 oncoprotein by human 
papillomavirus (HPV) has been shown to initiate cervical carcinoma and squamous 
cell carcinoma of the head and neck22,23. In human small-cell lung carcinomas (SCLC), 
more than 90% has an inactive form of RB24. Furthermore, in genetically modified 
mice, high penetrance of pituitary and thyroid tumours in Rb+/- mice as well as other 
tumours developed in mice subjected to Rb deletion highlights the causal event of Rb 
loss in many cancer types25.  
 TP53 has an antiproliferative role in response to various intracellular stresses 
such as excessive damage to the genome or suboptimal levels of growth-promoting 
signals. It can stop any further cell-cycle progression until such conditions are 
normalized. Apoptosis can also be triggered by TP53 for those irreparable damages9. 
Loss of such functions would allow for proliferative freedom and an increase in the 
accumulation of genomic mutations that favours cancer survival.  In almost every type 
of cancer, somatic mutations of TP53 occur at rates up to around 50%26. The main 
mode of TP53 inactivation is through single-base substitution mutations26. TP53 
mutations can also be inherited causing predisposition to early-onset cancers that 
includes breast cancers26,27.  
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1.1.1.3 Resisting cell death 
 Cancer cells encounter a number of physiological stresses as they progress 
through tumour formation that triggers the signalling circuitry involved in the apoptotic 
program. Such apoptosis-inducing stresses includes imbalances in signalling due to 
elevated levels of oncogene signalling as well as DNA damage caused by 
hyperproliferation9. Overcoming this programmed cell death machinery is the third 
core hallmark of cancer survival.  
 The apoptotic machinery is regulated by two major programs, which are the 
extrinsic and the intrinsic apoptotic program. The intrinsic program involving signals of 
intracellular origin are more widely implicated as a barrier to cancer pathogenesis9. 
The Bcl-2 family primarily regulates the intrinsic program by functioning as a ‘life/death 
switch’ through the interactions between proteins of three subfamilies. The prosurvival 
subfamily protects cells exposed to a variety of cytotoxic conditions whereas the Bax-
like subfamily and the BH3-only subfamily are proapoptotic28. The control of tissue 
homeostasis requires a balance between the levels of prosurvival and proapoptotic 
family members. Bax-like subfamily acts downstream of BH3-only subfamily to induce 
apoptosis28. BCL-2 was first implicated in cancer through its involvement in the t14;18 
chromosome translocation that causes follicular lymphoma suggesting an oncogenic 
potential of antiapoptotic Bcl-2 family members29. In contrast, examination of human 
lymphomas has revealed that the BIM gene, a member of the BH3-only subfamily, has 
undergone biallelic deletion and has also been silenced by promoter methylation in 
some other B-cell lymphomas30. This suggests a tumour suppressive role of the BH3-
only subfamily that cancer overrides.   
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1.1.1.4 Enabling replicative immortality 
 Normal cell lineages in the body behave in a way where they could only pass 
through a limited number of successive growth-and-division cycles. This limitation is 
associated with two distinct barriers to proliferation, namely senescence and crisis9. 
Senescence is an irreversible process when cells enter into a nonproliferative but 
viable state, whereas crisis involves cell death. Cells propagated in culture go through 
a number of repeated cycles of cell division that results in the induction of senescence 
and if they circumvent this barrier, a crisis phase is introduced to kill majority of cells 
in the population. Despite that, some cells do survive the crisis phase and exhibit 
unlimited replicative potential and are then known to be immortalized9.  
Telomeres are made up of multiple tandem hexanucleotide repeats. These are 
shorten progressively in non-immortalized cells that are propagated in culture31. 
Eventually the ability to protect the ends of chromosomal DNAs from end-to-end 
fusions is lost, which results in the formation of unstable dicentric chromosomes that 
affects cell viability. Telomere protection of the ends of chromosomes have been 
shown to be integral in the acquired capability of unlimited proliferation. This protection 
is carried out by the enzyme telomerase, a specialised DNA polymerase that adds 
telomere repeat segments to the ends of telomeric DNA32. Telomerase is almost 
absent in nonimmortalized cells but expressed significantly high in around 90% of 
spontaneously immortalized cells that include human cancer cells33. Moreover, 
telomerase reverse transcriptase (TERT) gene promoter mutations are considered the 
most common noncoding mutations in cancer as observed in majority of primary 
melanomas (67%-85%), glioblastomas (28%-84%), liposarcomas (74%-79%), and 
urothelial cancers (47%)32. Therefore, this shows that continued extension of telomeric 
- 10 - 
 
DNA enables cancer cells to counter the progressive telomere erosion as seen in 
normal cells. 
 
1.1.1.5 Inducing angiogenesis 
 Tumour-associated neovasculature provides sustenance to the tumours in the 
form of nutrients and oxygen as well as the ability to evacuate metabolic wastes and 
carbon dioxide. These vessels are produced through the process of angiogenesis as 
seen during embryogenesis and would healing. Constant activation of an “angiogenic 
switch” during tumour progression causes normal quiescent vasculature to continually 
grow new vessels in order to sustain the expanding neoplastic growths. This switch is 
governed by countervailing factors that either induce or oppose angiogenesis9.  
 The prototypical inducers and inhibitors of angiogenesis are vascular 
endothelial growth factor-A (VEGF-A) and thrombospondin-1 (TSP-1), respectively. 
VEGF-A gene encodes ligands that are involved in constructing new blood vessel 
growth during embryonic and postnatal development as well as in homeostatic survival 
of epithelial cells. VEGF signalling is carried out via three receptor tyrosine kinases 
(VEGFR-1-3)34. Tumour cells secrete VEGF into the microenvironment to stimulate 
the sprouting and proliferation of endothelial cells. This is one of the initiating steps for 
neovascularization in combination with other stimulatory signals in the tumour 
microenvironment such as the increase in platelet-derived growth factors to activate 
perivascular cells and the aberrant deposition of extracellular matrix proteins by 
tumour-associated fibroblasts35. Other proangiogenic signals exist such as members 
of the fibroblast growth factor (FGF) family36. In contrast, TSP-1 is a key 
counterbalance within the angiogenic switch. It binds transmembrane receptors 
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displayed on endothelial cells and releases suppressive signals that counteract 
proangiogenic stimuli37. It has been shown when the expression level of TSP-1 in 
tumour cells were compared to the stromal fibroblasts in patient samples with invasive 
ductal carcinoma, stromal TSP-1 in the early stages is high enough to inhibit 
neovascularization. Prolonged exposure of cells to TSP-1 may then promote hypoxia 
and an increase in VEGF secretion from tumour cells, thus overriding TSP-1 and 
stimulating angiogenesis38.  
  
1.1.1.6 Activating invasion and metastasis 
 The invasion-metastasis cascade depicts a succession of cell-biologic changes 
that begins with local invasion followed by intravasation of cancer cells into nearby 
blood and lymphatic vessels where they transit until extravasation of these cells into 
the parenchyma of distant tissues. Small nodules of cancer cells known as 
micrometastases are formed which will then eventually grow into macroscopic tumours 
through the process of “colonization”9.  
One characteristic that was clear as some cancer cells proceed through this 
cascade is that they lose E-cadherin, which is a key cell-to-cell adhesion molecule. E-
cadherin assembles epithelial cell sheets and maintain the quiescence of the cells 
within these sheets. Increased expression of E-cadherin is a well-known antagonist of 
invasion and metastasis39. Frequent loss of heterozygosity (LOH) of chromosome 16q 
where the human E-cadherin gene CDH1 resides were seen in gastric, prostate, 
hepatocellular and oesophageal carcinomas40. In addition, around 50% of all breast 
ductal carcinomas showed this formed of 16q LOH41. Conversely, N-cadherin, which 
is normally expressed in migrating neurons and mesenchymal cells is upregulated in 
- 12 - 
 
many invasive carcinoma cells. This form of upregulation can be seen in breast, 
pancreatic and prostate and carcinomas where it correlates with enhanced migration 
and invasion, increased metastasis and a poor prognosis39. Furthermore, a 
developmental regulatory program termed the “epithelial-mesenchymal transition” 
(EMT) has been implicated in the acquired ability of epithelial cells to invade, resist 
apoptosis and disseminate by co-opting a process involved in various steps of 
embryonic morphogenesis and wound healing42. This program is governed by a set of 
pleiotropically acting transcription factors (Snail, Slug, Twist, and Zeb1/2)43.  
 
1.1.2 Genome instability and mutation as enabling characteristics 
 The most prominent way of acquiring all the described core hallmarks of cancer 
is through successive alterations in the genome of neoplastic cells. Random mutations 
are generated and some confer a selective advantage on subclones of cells enabling 
their outgrowth. Therefore, a succession of clonal expansion is a portrayal of a 
multistep tumour progression. This expansion is triggered by an acquisition of an 
enabling mutant genotype or through nonmutational heritable phenotypes9,44.  
 In normal physiological conditions, mutation rates are kept very low due to the 
ability of genome maintenance systems to detect and resolve any defects in the DNA. 
Interestingly, this rate of mutation is often increased in cancer cells as they acquire the 
mutant genes for tumourigenesis45. This is achieved through increased sensitivity to 
mutagenic agents and through a breakdown in one or several components of the 
genomic maintenance machinery46. A number of defects have been documented in 
the “caretakers” of the genome that prevents detection and repairing of DNA damage 
as well as inactivating or intercepting further mutagenic molecules45,47. Additionally, 
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comparative genomic hybridization (CGH) analysis that documents gains and losses 
of gene copy number across the cell genome have revealed pervasive genomic 
aberrations in many tumours proving the loss of control of genome integrity48.  
 
1.2 Overview of kidney cancer 
In the UK 12,547 new cases of kidney cancer were documented in 2015, 
constituting 3% of all new cancer cases. It is the 7th most common cancer in the UK. 
The majority of kidney cancer cases were males with 63% of cases over females. This 
type of cancer is also strongly related to age with older people having the highest 
incidence rates49. More than a third of new cases in the UK in 2013-2015 were in 
people aged 75 and over. Importantly, 70-82% of kidney cancer cases in England, 
Scotland and Northern Ireland were diagnosed with one of the four stages of cancer 
compared to a diagnosis of an unknown stage. Furthermore, it has been projected that 
kidney cancer incidence rates will rise by 26% in the UK between 2014 and 2035 that 
involves a larger increase for males than females49. When compared to worldwide, 
kidney cancer is the 14th most common cancer50.  
Deaths from kidney cancer accounts for 3% of all cancer deaths placing it the 
13th most common cause of cancer death in the UK. Encouragingly, kidney cancer 
mortality rates are projected to fall by 15% in the UK between 2014 and 2035 which 
includes a smaller decrease for males than for females51. Overall, around 50% of 
patients with kidney cancer during 2010-2011 survive for 10 or more years in England 
and Wales. In fact, kidney cancer survival has been seen to increase in the UK in the 
last 40 years from 23% to 50% survival52.   
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1.2.1 Types of kidney cancer 
 The majority of cancers in the kidney (>90%) is one that originates from the 
renal epithelium (Figure 2), known as renal cell carcinoma (RCC). It encompasses a 
heterogeneous group of cancers derived from renal tubular epithelial cells53. The 
major subtypes of RCC include clear cell RCC (ccRCC) with around 70-80% of all 
RCC cases, papillary RCC (pRCC) with 10-15% of all RCC cases, and chromophobe 
RCC (chRCC) with 5% of all RCC cases54. In addition to these, other rare subtypes of 
RCC exist. The classification of these subtypes were done on the basis of their 
histologic appearance (Figure 3), the presence of distinct driver mutations, varying 
clinical course, and different responses to therapy55.  
Figure 2. Medical illustration of the human kidney. Source: https://www.cancer.net/cancer-
types/kidney-cancer/medical-illustrations 
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 Clear cell RCC are histologically defined by clear cytoplasm, with nested 
clusters of cells surrounded by a dense endothelial network. On the other hand, two 
subtypes of papillary RCC have been recognized (type I and type II) where diagnosis 
is mostly based on features of papillary architecture. Papillary RCC cells typically 
display a basophilic cytoplasm. Tumour cells from chromophobe RCC have a largely 
empty cytoplasm and a feature of low mitotic rate (Figure 3). Chromophobe RCC 
tumours have the lowest risk of developing metastases53,54,56.  
 The genetic feature most closely associated with the clear cell RCC is the loss 
or mutation of the von Hippel-Lindau (VHL) tumour suppressor genes that is identified 
in ~90% of sporadic cases57. The effects of this loss will be discussed further in section 
1.3. Apart from that, mutation or loss of heterozygosity of a large group of chromatin 
remodeling genes (PBRM1, BAP1, SETD2) and histone modifiers (KDM5a, ARID1a 
and UTX) has been associated with clear cell RCC58. Less is known about papillary 
RCC. It was shown that mutations in the MET proto-oncogene predispose people to 
Figure 3: Histology of the most common RCC subtypes. Source: Muglia VF, Prando A. 
Renal cell carcinoma: histological classification and correlation with imaging findings. 
Radiol Bras. 2015 
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multifocal papillary type I RCC. Mutations in the fumarate hydratase gene (FH) as seen 
in the syndrome of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) 
carries a risk for familial type II papillary RCC59. In the context of chromophobe RCC, 
most of these tumours harbor chromosomal losses, which includes loss of whole 
chromosome 1, 2, 6, 10, 13, 17, and 21. PTEN and TP53 tumour suppressor gene 
mutations have been identified in this RCC subtype60.  
 
1.2.2 Risk factors  
About a third of kidney cancer cases in the UK in 2015 were preventable 
whereby the major established risk for RCC include excess body weight, hypertension 
and cigarette smoking53,61. Indeed, 24% of kidney cancer cases were caused by 
overweight and obesity whereas 13% of cases were caused by smoking in the UK in 
201561. A report in a meta-analysis including 8,032 cases and 13,800 controls from 
five cohort studies compared smokers to never smokers and found a relative risk for 
smokers of 1.38 (95% confidence interval [CI]: 1.27-1.50)62. Apart from that, a 5kg/m2 
increase in BMI has been shown to be strongly associated with RCC63. Hypertension 
was shown to increase the long-term risk of RCC in men whilst a reduction in blood 
pressure lowered this risk64.  
A number of other medical conditions have been associated with RCC that 
includes chronic kidney disease, haemodialysis, kidney transplantation, acquired 
kidney cystic disease, a previous RCC diagnosis and diabetes mellitus53. Furthermore, 
contradictory reports were made on the association between red meat consumption 
and RCC risk, whilst moderate alcohol consumption seems to reduce this risk65–67. 
Genetic predisposition for RCC risk exist in the form of family history of renal cancer 
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with an approximate of twofold increased risk68. Mutation in at least 11 genes (BAP1, 
FLCN, FH, MET, PTEN, SDHB, SDHC, SDHD, TSC1, TSC2 and VHL) have been 
uncovered when familial RCC was interrogated which also includes some genes 
implicated in sporadic RCC development69. Genome-wide association studies 
(GWAS) of RCC have isolated six susceptibility loci that maps to EPAS1 (HIF2A), 
CCND1 (Cyclin D1), and BHLHE4170–72.  
 
1.2.3 Treatments currently in practice 
 Management of a surgically resectable RCC is usually dealt with surgical 
excision through either partial or radical nephrectomy. The type of surgical treatment 
depends on the clinical stage of the disease and to the general condition of the patient. 
Surgical options are not only reserved for localized disease but also for metastatic 
patients with cytoreductive intent53. Partial nephrectomy aims at removing the primary 
tumour completely while preserving the largest possible amount of healthy renal 
parenchyma. Stage I and II kidney cancer patients are prescribed with this surgical 
option along with RCC patients who only have one kidney. This surgical option offers 
lower renal function impairment compared to that of radical nephrectomy53. Indeed, 
radical nephrectomy consists of the removal of the kidney, perirenal fat tissue, adrenal 
gland and regional lymph nodes. This form of surgery is prescribed for kidney cancer 
patients in stage I – III53.  
The treatment of metastatic RCC have seen a number of approved targeted 
therapeutic agents and one immunotherapy agent over the past decade. Due to the 
highly vascular nature of the disease, several tyrosine kinase inhibitors targeting the 
VEGF signaling axis were approved in the United States and the European Union in 
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the first and second-line settings. These inhibitors include sorafenib, sunitinib, and 
axitinib73–75. In addition, mTOR inhibitors, everolimus and temsirolimus, are approved 
as single agents in the second-line setting as well as the first-line setting in patients 
with poor risk status76,77. The anti-VEGF monoclonal antibody bevacizumab is also 
approved for use as treatment with the cytokine interferon-a78. Newer generations of 
immunotherapy agents in the form of T cell immune checkpoint inhibitors are also 
being studied in combination with anti-VEGF therapy. These include avelumab, 
atezolizumab, nivolumab and pembrolizumab53. Out of the four new immunotherapy 
agents, nivolumab has been approved in the United States and the European Union 
after showing an overall survival benefit compared with everolimus79. Nivolumab is 
also combined with anti-VEGF therapies such as axitinib and bevacizumab which are 
now in several phase III studies for metastatic RCC treatment53.  
 
1.3 Clear cell renal cell carcinoma (ccRCC) 
 Renal cell carcinoma is mostly prevalent in the form of clear cell renal cell 
carcinoma (ccRCC), constituting 70-80% of all kidney cancers, of which its metastatic 
form is largely incurable. These tumours typically have yellow surface due to the high 
lipid content of the cells54. Histological assessment of ccRCC showed that it is 
composed of cells with clear or eosinophilic cytoplasm contained within a vascular 
network. Clear cell is given for this form of tumour due to its characteristic cytoplasm 
that is commonly filled with lipids and glycogen that are dissolved in histological 
processing leaving a clear cytoplasm surrounded by a distinct cell membrane54.  
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1.3.1 Molecular characteristic 
 A comprehensive study was carried out on primary nephrectomy specimens 
from patients with histologically confirmed ccRCC whereby clinical and pathological 
features, genomic alterations, DNA methylation profiles, and RNA and proteomic 
signatures were evaluated. Analysis of 417 of these samples showed, through DNA 
hybridizations, that recurrent arm-level and focal somatic copy number alterations 
(SCNAs) is observed at fewer sites than other cancers58, Out of the SCNAs observed, 
entire chromosomes or chromosome arms were more involved and the most frequent 
arm-level event involved the loss of chromosome 3p (91% of samples). This 
encompasses all of the four most commonly mutated genes (VHL, PBRM1, BAP1 and 
SETD2). Frequent arm level losses on chromosome 14q was also observed in 45% of 
samples that associates with the loss of HIF1A, which has been predicted to drive 
more aggressive disease. Chromosome gains of 5q were observed in 67% of samples. 
Moreover, focal amplification implicated genes such as PRKCI, MECOM, MDM4, MYC 
and JAK2. Focally deleted regions include tumour suppressor genes such as 
CDKN2A, PTEN, NEGR1, QKI, CADM2, PTPRD and NRXN358. Whole-exome 
sequencing (WES) of tumours from 417 patients identified nineteen significantly 
mutated genes (SMGs). The eight most extreme members include VHL, PBRM1, 
SETD2, KDM5C, PTEN, BAP1, MTOR and TP53. Epigenetic silencing of VHL was 
also observed in about 7% of ccRCC tumours and this is mutually exclusive to that of 
VHL mutations. This highlights the central role of the VHL locus in ccRCC58.  
 More than 800 VHL mutations have been identified in both hereditary and 
sporadic ccRCC80, some of which can be seen in Figure 4. Greater than 50% of these 
mutations are frameshift and nonsense mutations where it is highly likely to cause loss 
of pVHL function leading to HIFA stabilisation81,82. Missense mutations of VHL that are 
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destabilising mutations in the interface of HIFA and elongin B are associated to a 
prevalence of ccRCC, whereas mutations in the elongin C interphase were 
predisposed to developing pheochromocytoma83. Specifically, the majority of VHL 
missense mutations in exon 1 predispose to ccRCC by affecting whole protein stability 
Figure 4: An illustrative domain of the pVHL protein and a table of VHL mutations in 
sporadic ccRCC cases. Source of table: Rechsteiner MP et al. VHL Gene Mutations and 
Their Effects on Hypoxia Inducible Factor HIFa: Identification of Potential Driver and 
Passenger Mutations. Cancer Research, 2011. 
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compared to those mutations in exon 3. Essentially majority of these VHL missense 
mutations affect the stability of both HIFA isoforms83.  
 More recently, studies from the Tracking Renal Cell Cancer Evolution through 
therapy (TRACERx Renal) program were published to aid an evolutionary 
classification of RCC. From the analysis of 1,206 primary tumour regions from 101 
patients recruited into the multi-centre prospective study, they detected 751 driver 
SCNAs84. At the clone level their analyses of event co-occurrences observed an 
enrichment for mutual exclusivity between BAP1 and SETD2/PBRM1 mutations. They 
also observed a subset of cases that harboured two or more additional clonal driver 
mutations, aside from VHL84. This study also delineated the order of events occurring 
during ccRCC evolution that confirmed VHL as a universally preceding event. In 
addition, PBRM1 mutations were found to consistently precede PI3K pathway 
mutations, SETD2 mutations, and driver SCNA events. Moreover, seven evolutionary 
subtypes of ccRCC were defined84. Integrated analysis of 575 primary and 335 
metastatic biopsies across 100 patients with metastatic ccRCC showed that only a 
minority of events (5.4%) were found to be de novo in metastases85. Importantly, 9p 
loss was found to be a potent driver of both metastasis and ccRCC mortality risk. 
Furthermore, loss of 14q together with 9p loss represents the hallmark genomic 
alterations in ccRCC metastasis with 71% of the metastatic cases in the TRACERx 
renal cohort had loss of both 9p and 14q compared to 35% in cases without metastatic 
disease85. Finally, analysis of whole genomes from 95 biopsies across 33 patients with 
ccRCC showed that early development of ccRCC follows strongly preferred 
evolutionary trajectories with chromosome 3p loss often the initiating driver86. This 
seemingly arises in childhood or adolescence even though the cancer may not be 
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diagnosed for another 30-50 years, offering a long therapeutic window in which to 
deploy an effective therapy86.  
   
1.3.2 VHL tumour suppressor gene 
 The von Hippel-Lindau (VHL) disease is a hereditary, autosomal-dominant, 
neoplastic disease that comprises of various tumour types, including ccRCCs, central 
nervous system (CNS) and retinal haemangioblastomas, phaeochromocytomas 
(PCCs) and pancreatic neuroendocrine tumours. VHL disease can be classified into 
type 1 or type 2 depending on the absence or presence of PCCs, respectively. Type 
2 VHL disease can then be subdivided into 3 subgroups (2A, 2B, and 2C)87. These 
classifications are also based on types of VHL mutations present and their biochemical 
correlates. For example, type 1 VHL disease that includes ccRCC, is associated with 
nonsense and frameshift mutations that generates VHL-null alleles. Type 2 VHL 
disease is mainly characterized by missense mutations83.  
 In the 1980s, linkage studies placed the VHL gene at chromosome 3p25, which 
is a region of the genome frequently altered in sporadic kidney cancer88. This is 
followed by successful isolation and authentication of the VHL gene in 1993 by 
positional cloning89. VHL disease patients harbour a single mutant allele at the VHL 
locus on chromosome 3p, with one wild-type VHL allele and one defective VHL allele. 
The spontaneous inactivation or loss of the second wild-type VHL allele results in 
tumour development. Indeed, somatic biallelic inactivation of VHL occurs in most 
sporadic ccRCCs90. The tumour suppressive role of VHL gene was evidenced from 
studies of loss of heterozygosity (LOH) that showed inactivation of both VHL alleles is 
crucial in neoplastic development in VHL disease and sporadic non-hereditary 
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ccRCC91,92. It was also proven through the reintroduction of wild-type, but not mutant, 
VHL gene product (pVHL) into a VHL-null ccRCC cell line that inhibited the ability to 
form tumours in nude mice. This VHL mutant is a C-terminal truncation mutant that 
lacks a region frequently altered in sporadic and VHL-related renal carcinomas93. 
 The ubiquitously expressed VHL gene consists of three exons and encodes two 
isoforms of pVHL; a 213-amino-acid, 30kDa form (pVHL30) and a 160-amino-acid, 
19kDa form (pVHL19). The pVHL19 form lacks a 53-amino-acid amino-terminal 
pentameric acid repeat domain. Functional studies have suggested both isoforms 
have equivalent effects in assays and that both have tumour suppressor activity in 
vivo90,94. Biochemical studies on pVHL showed that it forms a ternary complex with the 
transcription elongation factors C and B (elongin C and elongin B) known as the VCB 
complex95. Structurally pVHL consists of two tightly coupled domains, α and β. The β-
domain consists of seven strands arranged in two β-sheets arranged as a sandwich 
with an α-helix on top. A substrate docking site resides in the β-domain. The α-domain 
directly contacts elongin C and it consists of three α-helices whereby the H4 helix of 
elongin C fits into an extended groove formed by the H1, H2 and H3 helices of the α-
domain90. This VCB complex nucleates a complex consisting of cullin 2 (CUL2) and 
the RING finger protein RBX1 to form the VCB-CR complex. This shows that elongin 
B and elongin C act as adaptors between the substrate-recognition subunit of the 
VCB-CR complex (pVHL) and the heterodimers CUL2 and RBX1. pVHL is stabilized 
and resistant to proteasomal degradation once associated with elongins B and C whilst 
mutations in pVHL disrupts elongin binding and renders them unstable and thus 
degraded57,96. But not all VHL mutations cause loss of binding to elongins B or C. 
Some missense mutations were seen to be located in the core of pVHL and not on the 
surface where the binding domains of HIFa, elongin B, and elongin C are located83. 
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 Up until 2010, VHL was the only gene that was known to be frequently mutated 
in ccRCC and the potential of VHL mutational status as a predictive biomarker in 
sporadic ccRCC was tested97. But there is no clear evidence that presence or absence 
of VHL mutations alone, or their type, could influence the outcome of this disease. One 
possible explanation is that a combination of VHL mutational status and other 
molecular markers downstream of VHL might prove to be better prognostic markers 
than VHL alone90. This is referring to the interactions between pVHL and hypoxia 
inducible factors (HIFs) in the VHL/HIF pathway and the subsequent effects on the 
expression of HIF-target genes. 
 
1.3.3 pVHL-HIF pathway  
The interaction between pVHL and HIFs was first documented in the regulation 
of hypoxia-inducible factor 1A (HIF1A)98. The pVHL-HIF pathway is a regulatory 
pathway that targets HIFs for polyubiquitylation and proteasomal degradation. With 
adequate oxygen supply, HIFA (HIF1A and HIF2A) is hydroxylated by prolyl-
hydroxylase domain (PHD)-containing enzymes on specific residues (Pro402 and 
Pro564 in human HIF1A; Pro405 and Pro531 in human HIF2A) within its oxygen-
dependent degradation domain (ODD)99. The VCB-CR complex as mentioned in 
section 1.3.2 has ubiquitin ligase activity and hydroxylated HIFA peptide binds 
exclusively to the β-domain of pVHL within the VCB-CR complex. This in turn triggers 
the E3-ubiquitin ligase component of the VCB-CR complex to polyubiquitylate 
recognised HIFA and targets it for proteasomal degradation by the 26S proteasomes 
(Figure 5)100. The polyubiquitylation of HIFAs is triggered by RBX1-dependent 
neddylation of CUL2 that increases the activity of VCB-CR complex. Neddylation is 
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the process of conjugating proteolytic processed NEDD8, which is a ubiquitin-like 
protein, on to a lysine residue in the target protein through an isopeptide bond101.  
In conditions such as hypoxia, pharmacological inhibition of prolyl-
hydroxylases, or in the absence of functional pVHL irrespective of oxygen tension, 
HIFA subunuits are not degraded102. Stabilized HIFA translocates to the nucleus 
where it binds to a HIFβ subunit, ARNT103. HIFA/ARNT heterodimers then binds to the 
HIF-DNA consensus-binding sites on the hypoxia-responsive element (HRE) along 
with transcriptional co-activators such as CBP/p300. The HRE comprises of a core 5’-
[A/G]CGTG-3’ consensus sequence with highly variable flanking sequences in the 
promoters of HIF-responsive genes104. This assembled transcriptional complex then 
Figure 5: Illustration of the pVHL-HIF pathway. Under normoxia, HIFα is fated to be 
hydroxylated and thus targeted for proteasomal degradation through the binding of the 
pVHL-E3-ubiquitin ligase complex. During hypoxia or the loss of functional pVHL, HIFA 
subunits escape degradation and translocated into the nucleus where they trigger the 
expression of HIF-target genes. 
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transactivates a specific subset of genes that are involved in the regulation of cellular 
adaptive response to hypoxia or in the progression of tumorigenesis (Figure 5)105. 
 
1.3.3.1 Hypoxia inducible factors 
 Hypoxia-inducible factors (HIFs) are basic helix-loop-helix-PER-ARNT-SIM 
(bHLH-PAS) proteins that consist of a heterodimer comprising an oxygen-labile alpha-
subunit (HIFA) and a constitutively expressed β-subunit (HIF1β or ARNT). The 
heterodimer HIFA exist in three isoforms (HIF1A, HIF2A (encoded by EPAS1) and 
HIF3A) in humans that shares a common oxygen-dependent degradation domain 
Figure 6: Different isoforms of HIFA. HIF proteins consist of several conserved domains 
that are involved in DNA binding (basic Helix-Loop-Helix, bHLH), protein-protein 
interactions and dimerization (PER-ARNT-SIM, PAS-A, PAS-B, and PAS-associated C-
terminal domain), transcriptional activation (N-TAD, C-TAD) and oxygen-dependent 
degradation (ODD).  
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(ODD) and an N-terminal transactivation domain (NTAD). In addition, HIF1A and 
HIF2A possess a C-terminal transactivation domain (CTAD) (Figure 6)105,106.  
 HIF1A was first described in 1995 when it was shown to have a central role in 
mediating oxygen-dependent transcriptional processes. This is followed by the 
identification of HIF2A (EPAS1) in 1997. Of the two isoforms, HIF1A is thought to be 
ubiquitously expressed in nearly all cell types, whereas RNA in situ hybridization of 
mouse embryos showed that the mRNA and protein expression of HIF2A is more 
abundant to blood vessels107. It was also identified that HIF2A protein was present in 
hypoxic rat kidney, lung and colonic epithelia, as well as in hepatocytes, macrophages, 
muscle cells and astrocytes108. These findings suggest that both HIF1A and HIF2A 
are co-expressed in many cell types. On the other hand, HIF3A subunit exist in multiple 
isoforms due to its mRNA being differentially spliced. These HIF3A isoforms either 
promote or inhibit the activity of other HIF complexes but little is known about the 
impact of HIF3A on tumour progression in hypoxic conditions107,109.  
 HIF1A and HIF2A transcription factors are both able to bind the same 
consensus sequence on the HRE and they regulate a number of target genes that are 
involved in diverse biological pathways. This includes angiogenesis, self-renewal, 
cellular proliferation, epithelial-mesenchymal transition (EMT), metastasis, and 
apoptosis to name a few110. According to genome-wide chromatin 
immunoprecipitation combined with DNA sequencing or mRNA microarray 
experiments, the number of direct HIFA target genes are currently >800 genes111,112. 
Some of the examples of these target genes include those involved in the distribution 
of the available oxygen supply such as EPO, VEGF and ANGPT1113. The chemokine 
receptor CXCR4, that has been implicated in metastatic progression, is also a direct 
downstream target of HIF2A114. HIFAs also indirectly regulate gene expression by 
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transactivating genes that encode for microRNAs and chromatin-modifying 
enzymes115–117. Furthermore, HIF1A and HIF2A also target genes that differ in a 
context dependant manner. HIF1A predominantly transactivate the target genes 
during acute hypoxia, whereas HIF2A starts to exert more of an influence with 
prolonged hypoxia118. The presence of two distinct transactivation domains (TADs) 
confers HIF1A and HIF2A with both common and unique regulatory properties. The 
C-TAD acts to regulate the transactivation of target genes common to both HIF1A and 
HIF2A through coactivator recruitment. The N-TADs of HIF1A and HIF2A confer target 
gene selectivity between these two family members through the action of distinct 
transcriptional cofactors recognizing the N-TAD of HIF1A versus HIF2A110.  
 A very recent study published a systematic analysis of the pan-genomic 
distributions of the two major isoforms of HIF, HIF1A and HIF2A.  Remarkably, it was 
found that there is a strong support for intrinsically distinct patterns of binding between 
the two HIF isoforms119. The disruption of either HIFA gene had very little effect on the 
binding of the other. Moreover, there was little evidence for cross-compensation at 
sites that bound both HIFA isoforms too in wild-type cells119. Importantly, when the 
distribution of HIF binding was considered in relation to the distribution of available 
HRE at gene loci, there was a clear bias for HIF2A to bind more distantly from the 
promoter. In contrast, a clear bias was also seen for HIF1A to bind more closely to the 
promoter119. Additionally, the ratio of HIF1A to HIF2A was found to be very similar in 
sites that were common across different cell types. This highlights individually distinct 
binding patterns for HIF1A and HIF2A whereby they function more independently that 
could be utilized for isoform-specific therapeutic inhibitors119.  
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1.3.4 HIF2A vs HIF1A 
  Despite the fact that VHL similarly targets both HIF1A and HIF2A for 
degradation, multiple lines of evidence from different functional assays suggest that 
HIF2A, not HIF1A, is the critical mediator of ccRCC formation downstream of VHL 
loss. For example, many VHL-defective renal carcinoma cells like 786-0 and KTCL140 
cells expressed HIF2A at a constitutively high level but with no detectable HIF1A98. 
Importantly, recent experimental studies showed that wild-type HIF1A suppresses 
renal carcinoma growth, while the production of aberrant mRNAs and proteins due to 
a homozygous deletion of the HIF1A locus on chromosome 14q in ccRCC cell lines 
do not120. In addition, HIF1A-proficient renal carcinoma cell lines with the 
downregulation of HIF1A propagated in vivo after being injected into the kidneys of 
mice120. Indeed 786-0 renal carcinoma cells re-expressing wild-type VHL together with 
a stable HIF1A mutant that could not bind to VHL is not sufficient to cause 
tumorigenesis121. In contrast, suppression of HIF2A abrogated tumour formation by 
pVHL-defective renal carcinoma cells in mice122, while stable mRNA and protein 
expression of a mutant HIF2A that does not bind pVHL in normoxia rescues the 
tumorigenic phenotype in 786-0 tumour cells transfected with wild-type VHL123.  
Another line of evidence supporting the importance of HIF2A over HIF1A in 
ccRCC comes from genetic and immunohistochemical analysis of ccRCC patient 
samples. First, genome-wide association studies have identified two single nucleotide 
polymorphisms (SNPs) that are linked with higher incidence of ccRCC, both of which 
map to the EPAS1 locus encoding HIF2A70. Second, immunohistochemical analysis 
of 160 primary tumours have subdivided the tumours into 3 groups with distinct 
molecular characteristics: VHL wild type and no detectable HIFA (VHL WT); VHL-
deficient expressing both HIF1A and HIF2A (H1H2); and VHL-deficient expressing 
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only HIF2A (H2). Tumours of H2 showed enhanced MYC activity and higher rates of 
proliferation relative to H1H2 tumours, suggesting the existence of two biologically 
distinct types of VHL-deficient ccRCCs124. In a different study, out of 45 primary renal 
tumours, it was shown that HIFA is upregulated in the majority of ccRCC with a pattern 
of expression biased toward the HIF2A isoform. Moreover, these observed 
upregulations of HIFA in ccRCC involved both increased mRNA and protein 
expression highlighting an involvement of a VHL-independent mechanism125. 
Collectively, these studies highlight an important role for HIF2A, not HIF1A in ccRCC 
tumorigenesis. 
 
1.3.5 CXCR4 in tumorigenesis 
 Chemokine receptors are part of a large family of proteins that mediate 
chemotaxis of cells towards a gradient of chemokines. A G-protein coupled chemokine 
Figure 7: Crystal structure of the transmembrane protein CXCR4. Source: Wu B, Chien 
EYT, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine 
GPCR with small-molecule and cyclic peptide antagonists. Science. 2010. 
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receptor gene, CXCR4, is located at chromosome locus 2q21. This receptor is made 
up of a seven-transmembrane structure with seven helical regions connected by six 
extramembrane loops (Figure 7)126. CXCR4 is expressed in multiple cell types such 
as lymphocytes, hematopoietic stem cells, endothelial cells, epithelial cells, cancer 
cells and stromal fibroblasts127. By binding its chemokine ligand CXCL12, CXCR4 
activates the mitogen-activated protein kinases (MAPK) signalling pathway that leads 
to alteration of gene expression, actin polymerisation, cell skeleton rearrangement and 
cell migration126,128. In embryonic development, CXCR4 is expressed on progenitor 
cells, which allows them to migrate from their place of origin to their final destination 
where they will differentiate into organs and tissues129. Expression of CXCR4 in 
phagocytic cells from the innate immune system such as neutrophils and 
macrophages allows them to migrate along a gradient of CXCL12 present at sites of 
inflammation130. 
 CXCR4 is known to be overexpressed in more than 20 human tumour types 
that includes ovarian, prostate, oesophageal, and renal cell carcinoma131–134. 
Amplification of the CXCR4 gene locus was also suggested to be an early event in the 
development of high-grade serous ovarian cancer135. CXCR4 was proven to play a 
role in tumour growth when CXCR4 antagonists managed to inhibit tumour growth in 
experimental orthotopic, subcutaneous human xenograft and transgenic mouse 
models136–138. Treatment with CXCR4 inhibitor CTCE-9908 in transgenic breast 
cancer mouse model reduces 56% of primary tumour growth rate compared to controls 
138. According to preclinical models of thyroid, prostate and colon cancer, CXCR4 
activation directed metastasis of cancer cells and migration of cancer cells towards 
CXCL12 expressing organs132,137,139. For instance, bone marrow, liver, lungs and 
lymph nodes exhibit peak expression levels of CXCL12 mRNA and represent the most 
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common target organs for breast cancer metastasis140. Furthermore, targeting CXCR4 
in experimental metastatic mouse models impaired the spread of cancer cells and 
development of metastasis in breast cancer, colon cancer, and renal cell 
carcinoma139–141. Based on the findings above, CXCR4 plays a decisive role in tumour 
growth and metastasis. 
 
1.3.6 Alternative treatments against ccRCC progression 
 As described in section 1.2.3, drugs that modulate the pVHL-HIF-VEGF 
pathway has proven to be beneficial in treating ccRCC making it the standard of care 
for patients with metastatic ccRCC disease. However, these treatment options also 
results in the development of resistance in VHL-deficient ccRCC patients calling for 
alternative treatments142. The prominence of functional pVHL loss in ccRCC may 
suggest possible synthetic lethal interactions in the cells. Synthetic lethality of two 
genes is when mutation of either alone is viable for the cells but mutation of both leads 
to cell death143. This means a synthetic lethal gene can be targeted with drugs that 
might preferentially kill ccRCC cells that harbours a mutant VHL. A small-molecule 
synthetic lethality screen identified a compound called STF-62247 that selectively 
induces autophagic cell death in VHL-deficient cells but not in those expressing wild-
type VHL144. Another compound was also identified from the same screen, STF-31, 
which inhibits glucose uptake GLUT1 and exhibits enhanced cytotoxicity against VHL-
deficient ccRCC145. Moreover, a separate synthetic-lethality screen that used shRNAs 
against 88 kinases reported that silencing of CDK6, MET and MEK1 preferentially 
inhibited the growth of VHL-null cells146.  
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 The antiangiogenic drugs that are being used for ccRCC treatments only 
targets a part of the downstream genes regulated by HIF2A. Direct targeting of HIF2A 
may translate into a more effective downstream pathway inhibition147. However, HIF2A 
is challenging for pharmacological development with it being an intracellular protein 
complex without active sites typically used for small-molecule binding. In fact, 
transcription factors are considered “undruggable” as they usually reside in an 
extended conformation, thus requiring disruption of protein-protein or protein-DNA 
interactions for ligand binding148.  
 Nevertheless, a study have shown that the PAS-B domain of the HIF2A subunit 
contains a relatively large cavity where an unknown cofactor induces allosteric 
conformational changes149. This finding would potentially allow specific targeting of 
HIF2A, and not HIF1A, as it lacks a comparable ligand binding place. It was proven 
that this cavity can be bound by small-molecule ligands, using NMR-based screens of 
small fragment libraries. This induces conformational changes that impairs 
heterodimerization of HIF2A with HIF1β, thus disrupting HIF2A DNA binding and 
transcription of its target genes. More than 130 co-crystal structures of inhibitors were 
generated that led to the selection of PT2385 and PT2399 as the clinical 
candidates150,151.  
 PT2385 is a specific antagonist of HIF2A by allosterically blocking its 
dimerization with HIF1β. This antagonist inhibited the expression of HIF2A-dependent 
genes such as VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumour 
xenografts. Moreover, favourable pharmacokinetic properties and a good safety profile 
was shown in preclinical studies of PT2385. It has been shown to have a faster and 
larger tumour reductions in subcutaneous xenograft models compared to sunitinib, 
axitinib or pazopanib152. The antagonist PT2399 is currently under preclinical 
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development and has been shown to dissociate HIF2A in human ccRCC cells and 
suppresses tumourigenesis in 56% of such lines. It has greater activity and better 
tolerated compared to sunitinib. One caveat to these antagonists is that differential 
sensitivities from VHL-mutant ccRCCs were observed153,154. Taking these findings 
together with resistance arising from the established treatments against ccRCCs, 
more investigation is needed into other potential novel therapeutic targets.  
 
1.4 Genetic screening 
 Genetic analysis is carried out to identify which genes cause a certain biological 
phenotype of a particular disease. For many years, hypothesis-driven genetic methods 
have dominated whereby a prior knowledge was used to test a causal role of specific 
genetic perturbations. This approach takes a ‘genotype-to-phenotype’ method of 
investigation. In contrast, genetic screens employ a ‘phenotype-to-genotype’ method 
that firstly involves modifying or modulating the expression of a number of genes. Cells 
or organisms with a phenotype of interest are then selected for, and finally the genetic 
mutations that causes those phenotype changes are characterized155.  
 
1.4.1 Development of screening methods 
 Initial genetic screening methods applied the use of chemical DNA mutagens 
in a number of model organisms followed by the isolation of those with aberrant 
phenotypes155. This approach managed to uncover a number of basic biological 
mechanisms including the RAS and NOTCH signalling pathways156. A major setback 
of this form of screen perturbation is that the causal mutations in the selected clones 
are initially unknown, therefore making it costly and labour intensive to determine 
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them. Furthermore, random mutagenesis results in mutants that are typically 
heterozygotes that can mask the recessive phenotypes155.  
 The discovery of RNA interference (RNAi) pathway revolutionized genetic 
screening strategies. This pathway was first seen in Caenorhabditis elegans that is 
conserved in most eukaryotic species. Since then several species of small noncoding 
RNAs have been discovered157. All of these small RNAs are embedded in a member 
of the Argonaute (AGO) protein family where they act as guides to specific target 
molecules. This conserved endogenous RNAi pathway can target mRNA molecules 
for degradation based on sequence complementarity158,159. Some of the developed 
RNAi reagents include long double-stranded RNA (dsRNA), synthetic small interfering 
RNA (siRNA), short hairpin RNA (shRNA), and shRNAs embedded in microRNA 
(miRNA) precursors (shRNAmirs)155.  
 Cancer vulnerabilities were uncovered through large-scale combinatorial RNAi 
screens by identifying genes that are essential in various cancer cell lines. Drug 
targets for cancer therapy were yielded from such screens160. RNAi screenings in vivo 
in mice have also been carried out in a systemic loss-of-function manner. For example, 
screens in mice with shRNA have identified bromodomain-containing protein 4 (BRD4) 
as a therapeutic target in acute myeloid leukaemia as well as novel regulators of 
oncogenic growth in a HrasG12Vmouse model of skin tumorigenesis161.  
Functional genetic studies have clearly been enhanced by the use of RNAi in 
genetic screens but one major setback is that their utility were hindered by incomplete 
gene knockdown and extensive off-target activity162,163. The emergence of a 
sequence-specific programmable nucleases, that utilises the RNA-guided 
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endonuclease Cas9, as a new genetic perturbation system that targets the DNA itself 
for modification would overcome the problems faced in RNAi screens155.   
  
1.4.2 CRISPR-Cas9 technology 
 The clustered regularly interspaced short palindromic repeat (CRISPR) DNA 
sequences were initially noticed in Escherichia coli and they are separated by non-
repeating DNA sequences called spacers164. These CRISPR sequences are present 
in more than 40% of sequenced bacteria as well as 90% of archaea165. Adjacent to 
the CRISPR elements are multiple well-conserved genes called CRISPR-associated 
Figure 8: CRISPR-Cas9 system. Cas9 consists of two active sites that each cleaves one 
strand of a double-stranded DNA molecule. This RNA-guided Cas9 activity creates site-
specific double-stranded DNA breaks, which are then repaired through either non-
homologous end joining (NHEJ) or homology-directed repair (HDR). Addition of template 
DNA during homologous recombination enables the insertion of new sequence information 
at the break site. 
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(Cas) genes. Interestingly, the non-repeating spacer DNA sequences were recognized 
to belong to viruses and other mobile genetic elements166. The experimental evidence 
that showed the potential of CRISPR systems were demonstrated after a viral 
challenge of Streptococcus thermophilus bacteria. The bacteria integrated new 
spacers derived from the genomic sequence of the phage into its genome. This spacer 
sequences of CRISPR determine the targeting specificity of Cas enzymes that 
provided the defence against the phage167. Then, it was found that the activity of Cas 
enzymes is guided by short CRISPR RNAs (crRNA) that is transcribed from the spacer 
sequences168.  
Collectively, CRISPR-Cas is a microbial adaptive immune system that acquires 
RNA-guided nucleases to cleave foreign genetic elements169. A key characteristic for 
the system to work is that the spacer sequences are highly similar to that of the regions 
called protospacer-adjacent motifs (PAMs) within the DNA target that varies according 
to the specific CRISPR system. Thus far, the best-characterised system is the Type II 
CRISPR system from Streptococcus pyogenes consisting of the nuclease Cas9 
(Figure 8), the crRNA array that encodes the guide RNAs and a required auxiliary 
trans-activating crRNA (tracrRNA) that facilitates the processing of the crRNA array 
into discrete units170. Due to its simple NGG PAM sequence requirements, S. 
pyogenes’ Cas9 (spCas9) is widely used in multiple applications. Every single crRNA 
unit contains a 20-nt guide sequence and a partial direct repeat. The guide sequence 
specifically directs Cas9 to a 20-bp DNA target via complementary base pairing 
(Figure 8). A single-guide RNA (sgRNA) can be made by fusing together the crRNA 
and tracrRNA, forming a chimera171. Hence, by altering the 20-nt guide sequence 
within the sgRNA, Cas9 can be re-directed toward any target of interest that is within 
immediate vicinity of the PAM sequence. Furthermore, RNA-guided nuclease function 
- 38 - 
 
of CRISPR-Cas is reconstituted in mammalian cells through the heterologous 
expression of human codon-optimized Cas9 and the requisite RNA components172. 
Cas9 nucleases carry out strand-specific cleavage by using the conserved HNH and 
RuvC nuclease domains and in the case for Streptococcus pyogenes Cas9, a blunt 
cut is known to be made three base pairs 5’ of the PAM in the target sequence171,173. 
 Genome engineering can be performed with the CRISPR-Cas9 technology 
through the stimulation of DNA double-stranded break (DSB) by Cas9 and the 
subsequent DNA damage repair by one of the two major repair pathways, non-
homologous end joining (NHEJ) or homology-directed repair (HDR) (Figure 8)174. 
Beyond genome editing, the CRISPR technology can be utilized for processes such 
as gene regulation, epigenome editing, chromatin imaging, RNA targeting and 
chromatin topology175.  
 
1.4.3 CRISPR-Cas9 based screens 
1.4.3.1 Knock-out screens 
 Loss-of-function mutations caused by Cas9 nucleases are achieved by 
targeting a DSB to a constitutively spliced coding exon. Cas9 is targeted to specific 
genomic loci with the help of sgRNAs that recognizes the target DNA through Watson-
Crick base pairing. Hence, Cas9 combines both the permanently mutagenic nature of 
classical mutagens and the programmability of RNAi155. When NHEJ repairs the 
DSBs, indel mutations can be introduced. This often results in a coding frameshift 
causing a premature stop codon and the initiation of nonsense-mediated decay (NMD) 
of the transcripts. In addition, early frameshifts or large enough indels might be 
sufficient to produce non-functional proteins155. Targeting early exons are more 
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preferred as indels in such exons would have a higher probability of introducing an 
early stop codon or a frameshift176.  
 Large-scale CRISPR-Cas9 screens have been conducted to systematically 
discover essential genes across a number of cancer cell lines177,178. Approximately 
1500 essential genes were identified in genome-scale CRISPR-Cas9 screens in ten 
cancer cell lines, which are five times higher than previously detected by shRNA 
screens178. In a screen to identify the essential genes for acute myeloid leukaemia 
(AML), eight AML cell lines were used to identify 429 candidates. From this screen, 
KAT2A was characterized as druggable and a leukaemia specific target179. Exons of 
chromatin regulatory domains were also targeted with CRISPR-Cas9 screens that 
revealed several novel domains that were essential for AML180. Furthermore, a similar 
screen identified that a mutation in the NPM1 gene harboured in AML cell lines 
specifically depend on the menin binding site of the MLL1 protein that can be 
pharmacologically inhibited for an anti-leukaemic effect181. The CRISPR-Cas9 
screens can also be used for synthetic lethality interactions as demonstrated in a 
genome-wide screen where pancreatic cell lines harbouring a mutation in the ubiquitin-
ligase RNF43 are especially vulnerable to the knockout of the Wnt ligand receptor 
FZD5182.  
 An in vivo CRISPR-Cas9 screen involves two concepts that include the 
implantation of ex vivo edited cancer cells and the in vivo delivery of CRISPR-Cas9 
components to mouse tissues to generate tumours168. High-throughput screening of 
sgRNAs in vivo can be achieved by transplanting ex vivo CRISPR edited cells. This is 
shown when a genome-wide CRISPR loss-of-function screen in murine lung cancer 
identified genes driving progression and metastasis183. Another loss-of-function 
screen was carried out with murine liver progenitor cells deficient of TP53 and 
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overexpressing MYC184. In addition, direct in vivo screening is also possible as 
demonstrated in a focused AAV-mediated CRISPR library into brains of conditionally 
Cas9 expressing mice that involved sequencing targeted genetic loci after visible 
tumour development185.  
 
1.4.3.2 Modified Cas9 screens 
 Gene expression can also be modulated at targeted loci without introducing 
irreversible mutations to the genome by utilising a catalytically inactive Cas9 (dCas9). 
The dCas9 comes with various fusions of transcriptional activator, repressor and 
recruitment domains155. This dCas9-based transcriptional inhibition and activation 
systems are commonly known as CRISPRi and CRISPRa, respectively. dCas9 itself 
can have a repressive effect on gene expression due to steric hindrance of the 
components of the transcription initiation and elongation machinery186,187. With the 
recruitment of chromatin-modifying repressor domains fused to dCas9, such as the 
Krüppel-associated box (KRAB) domain, along with efficient sgRNA targeting of the 
transcription start site, gene repression can be improved188. In contrast, synthetic 
activators were constructed by fusing dCas9 with transcriptional activation domains 
such as VP64 or p65. These synthetic activators along with the delivery of multiple 
sgRNAs targeting the same promoter region improved target gene activation189. 
Furthermore, a repeating peptide array of epitopes fused to dCas9 was developed 
with the activation domains fused to a single-chain variable fragment (ScFv) antibody 
to amplify the signal of dCas9190.  
 The feasibility of the CRISPRi method for genetic screening has been proven 
in a study that compared the strength of phenotypes obtained with CRISPRi to a 
- 41 - 
 
previously published shRNA data. What was concluded is that significant ricin 
phenotypes were seen for each of the 49 genes, and more interestingly, in every case 
the normalized ricin phenotype Z score is stronger than seen with a comparably-sized 
shRNA library191. Moreover, a combined CRISPRi/a-based chemical genetic screen 
utilising chemical libraries have identified rigosertib as a microtubule-destabilizing 
agent192.  
 
1.4.4 CRISPR-Cas9 knock-in reporters for precise genetic screens 
 Prior to the advent of CRISPR-Cas9 technology, reporters have been 
implemented in genetic screens in the form of reporter plasmids. They encode easily 
traceable proteins with its activity being affected by the cellular effect under 
investigation193. For example, the activity of a transcription factor or an entire signalling 
pathway that leads to the activation of a transcription factor can be interrogated using 
a reporter plasmid consisting of the promoter sequence for the DNA-binding moiety in 
front of a luciferase coding sequence193. Moreover, cell-fusion processes can also be 
followed by trans-complementation of an activated β-galactosidase by a polymerase 
that binds to and activate the reporter plasmid in the target cell. This method was 
applied for a screen that identified Fusin, now also known as CXCR4, which is a gene 
that encodes a seven-transmembrane G-protein-coupled receptor194. One limitation to 
the use of a reporter plasmid is the fact that it does not faithfully recapitulate the 
endogenous processes and environment within the cell. 
 CRISPR-Cas9 technology has enabled more sophisticated reporters to be 
established. These are produced through different knock-in methods of the reporters 
into the genome to be studied that are applied following double stranded break by the 
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Cas9 enzyme. Most reporter knock-in methods employed the homology-directed 
repair (HDR) pathway for precise and defined modifications at a target locus in the 
presence of an exogenously introduced repair template195. Either single-stranded DNA 
oligonucleotides (ssODNs) or conventional double stranded DNA targeting constructs 
with homology arms flanking the insertion sequence can be used as a repair template 
for reporter knock-in. The scale of the genome editing affects the type of repair 
template used196,197. Some examples of reporters generated through the use of 
CRISPR-Cas9-based HDR knock-in include the generation of fluorescent reporter and 
epitope tagged human pluripotent stem cells to facilitate studies on the pluripotency 
and differentiation characteristics of these cells198. Moreover, endogenous 
transcriptional reporters have also been developed for studies of the endogenous 
transcriptional landscape, with the potential in high-throughput genetic screen 
context199–201. Although it is known that the NHEJ repair pathway equates to possibility 
of insertions and deletions (indel) mutations, it occurs more predominantly compared 
to the HDR repair pathway195,202. This prompted studies to be taken on the use of the 
NHEJ repair pathway alongside CRISPR-Cas9 double stranded breaks for reporter 
knock-ins as it holds great potential on improving the efficiency compared to the HDR 
method. Successful knock-in of large reporter genes such as a 4.6kb promoterless 
IRES-EGFP has been generated in human cells through a homology-independent 
knock-in strategy203. Furthermore, CRISPR-Cas9 mediated homology-independent 
targeted integrations has also been shown in an in vivo genome editing setting204.  
 Importantly, these CRISPR-Cas9-based knock-in reporters have the potential 
of interrogating the endogenous environment of any gene of interest through high-
throughput functional screenings. Indeed, screening has been carried out using an 
exogenously introduced reporter with an endogenous promoter sequence cloned into 
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it205. This may have not recapitulated the endogenous environment of the PARKIN 
gene in question but the reporter cell lines produced in this study were successfully 
used in a genome-wide CRISPR-Cas9 pooled-based knockout screen to delineate the 
transcriptional repressor network including THAP11 that negatively regulates PARKIN 
abundance205. However, how such screens would apply to different cell lines 
especially mutated cancer cell lines with endogenously integrated reporter systems 
are yet to be explored.  
 
1.5 Research question 
  As outlined in detail above, ccRCC tumorigenesis is highly dependent on the 
VHL/HIF2A pathway specifically with high frequency of VHL loss seen in this form of 
carcinoma58,102. How would one explain the tissue specific nature of this 
tumorigenesis? As HIF2A is the main effector of ccRCC progression, its mRNA 
expression could be a determinant of that specificity. This means that if HIF2A mRNA 
expression level is not high enough, VHL loss does not provide any tumorigenic 
potential. Indeed, very little is known about the regulatory mechanism of HIF2A mRNA 
expression. Furthermore, HIF2A inhibition can lead to resistance through mutation in 
HIF2A153, suggesting the importance of the transcriptional programme of HIF2A for 
alternative therapy. Therefore, if HIF2A mRNA expression or activity can be inhibited, 
this could complement available therapies and prevent resistance.  
To best execute this interrogation, development of human-based genetically 
engineered fluorescent systems that preserves and faithfully recapitulate the 
endogenous regulatory environment of HIF2A can be achieved with CRISPR-Cas9 
technology. The specific aims for this project are as follows: 
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1. Development of reporter systems to monitor endogenous HIF2A mRNA expression 
levels in ccRCC. 
• HDR repair pathway has been widely applied to integrate transgene into 
endogenous gene, which utilizes homology arms for precise knock-in to 
preserve the endogenous genomic environment.  
• These reporter systems can be used to monitor changes in the mRNA 
expression levels of HIF2A in relation to perturbations of its potential 
regulators.  
2. Development of reporter systems to monitor endogenous HIF2A activity in ccRCC. 
• CXCR4 is a well-known downstream target of HIF2A and is involved in 
cancer progression and metastasis. 
• CXCR4 reporter systems would highlight novel factors involved in the 
activity of HIF2A within its regulatory landscape. 
• Alongside HIF2A reporter systems, the CXCR4 reporter systems could 
potentially build a comprehensive regulatory network of ccRCC progression. 
3. Use of these reporter systems for high-throughput analysis. 
• An unbiased screening approach to genetic perturbations implementing 
sgRNA libraries that target a large set of potential regulatory factors of 
HIF2A mRNA expression and activity.  
• Potential regulators can be isolated from such screens based on the effect 
its loss has on the fluorescence level of the reporter systems.  
• The effects shown by the isolated regulators would then be validated with 
single sgRNA perturbation experiments. 
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Chapter 2: Materials and Methods 
Cells and Reagents. Renal cancer cell lines 786-0, OS-RC2, and their metastatic 
derivatives 786-M1A, 786-M2A, 786-M2B and OS-LM1B, respectively, have been 
previously described206, and they were obtained from J. Massague (Memorial Sloan 
Kettering Cancer Center, New York) in 2014. UOK101 cell were obtained from the 
National Cancer Institute (NCI). RCC-JF, UMRC-6, 769-P, MF-LM1A, RFX393, RCC-
MF, RCC-ER, MF-LM1B, MF-LM1C, RFX631 and A498 renal cancer cell lines were 
obtained from J. Massague (Memorial Sloan Kettering Cancer Center, New York) in 
2014. The identity of all these renal cancer cell lines was confirmed by Sanger 
sequencing-based detection of known unique homozygous VHL mutations. The 
cancer cell lines have been confirmed negative for mycoplasma by biannual tests 
using the MycoAlert™ Mycoplasma Detection Kit (Lonza, LT07-318). Renal cancer 
cells were cultured in RPMI-1640. HEK293T cells, used for lentivirus production, were 
cultured in DMEM. Both media were supplemented with 10% fetal bovine serum 
(FBS), penicillin (100U ml-1) and streptomycin (μg ml-1). Cell lines were used in 
experiments within 10 passages from thawing. Spheroid growth of A4CXmC and 
M1CXmC cells were carried out using ultra-low attachment 6-well plates. The growth 
media used for spheroid formation is the DMEM/F-12 media that is supplemented with 
B-27 supplement, penicillin and streptomycin antibiotics, FGF and EGF growth factors.  
 
Plasmids and cloning. px330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene 
#42230)207, pKLV-U6gRNA(BbsI)-PGKPuro2ABFP (Addgene #50946)208 and pKLV-
U6gRNA(BbsI)-PGKHyg2AEGFP (adapted from Addgene #50946)208 were used for 
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sgRNA delivery. pHR-SFFV-dCas9-BFP-KRAB (Addgene #46911)209 and HIF2A-
targeting sgRNA constructs, cloned as previously described141, were used for HIF2A 
CRISPRi. Lenti-Cas9-EGFP (adapted from Addgene #52962)210 was used for HIF2A 
mutagenesis. Lenti-Cas9-Blast (Addgene #52962)210 was used to produce 786-M1A 
and A498 cells that constitutively-express Cas9 for the production of CXCR4 reporter 
systems. pLVX-puro (Clontech #632164) was used to express HA-VHL (Addgene 
#19234)211 for the VHL reintroduction experiments, whereby the empty vector (EV) of 
pLVX-puro was used as the control. Truncated version of pcDNA3.1(-) (adapted from 
Thermo #V79520) plasmid that was developed by David Hoffmann for the lab was 
used for HDR plasmid template cloning. pMC.BESPX-MCS2 (System Biosciences 
MN100B-1) were used as a parental plasmid for the production of all the minicircles. 
Primer sequences and sgRNA sequences used are listed below: 
No. Name Primer Sequence (5' - 3') 
1 EPAS1 Exon 16 sgRNA sequence TGGACCAGGCCACCTGAGCC 
2 EPAS1 cDNA Sequencing Primer Forward ATAAGTTCACCCAAAACCCC 
3 EPAS1 cDNA Sequencing Primer Reverse CCCTCGCCCTCGATCTCGAA 
4 EPAS1 Genomic Sequencing Primer Forward GGATTTTCAGACTGTTGAAT 
5 EPAS1 Genomic Sequencing Primer Reverse CCTACAGAAGAACAGACATG 
6 CXCR4 Genomic Sequencing Primer Forward CCTGTGGCCAAGTTCTTAGT 
7 CXCR4 Genomic Sequencing Primer Reverse AAATCAACCCACTCCTGAAA 
8 Scramble sgRNA sequence GAGTGTCGTCGTTGCTCCTA  and  GGAGATGCATCGAAGTCGAT 
9 iHIF2A-1 sgRNA sequence TCGCGAGTGTAAAGCTCCCG  and  ACAGTCTCAGGACACTGCCG 
10 iHIF2A-2 sgRNA sequence TGGCCCTCGTCCGCTCCCCG 
11 iHIF2A-3 sgRNA sequence ACAGTCTGGGCTTTTCTCCT  and  ACCGGGAGCAGGCGAGGGGC 
12 CTRL sgRNA sequence GAGTGTCGTCGTTGCTCCTA 
13 sgEPAS1-1 sgRNA sequence GAGTAGCTCGGAGAGGAGGA 
14 sgEPAS1-5 sgRNA sequence TGAGATTGAGAAGAATGACG 
15 sgHNF1B sgRNA sequence GACGTACCAGGTGTACAGAG 
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PCR amplification. This is carried out using the ACCUZYMETM DNA polymerase 
(Bioline). A standard 50μl reaction was carried out that is made up of 10x AccuBuffer, 
100mM dNTP Mix, 20μM of each primer, 2.5 U/μl of ACCUZYME DNA polymerase, 
DNA template as required along with water up to 50μl in total volume. The PCR cycling 
conditions used for amplification starts with an initial denaturation step at 95oC for 3 
minutes for one cycle. This is followed by a denaturation step at 95oC for 15 seconds, 
an annealing step of temperatures varied between 55oC – 60oC depending on the 
primers used for 15 seconds, and an extension step at 72oC for 2 minutes/kb. These 
three steps were repeated for 35 cycles. The resultant PCR product was checked 
using gel electrophoresis.  
 
Quantitative RT-PCR. Cells were trypsinized from 10cm dishes and pelleted. 1x PBS 
was used to wash cell pellets twice. Total RNA from cells was purified using RNAzol® 
RT RNA Isolation Reagent (Sigma). Cells were trypsinized and pelleted prior to RNA 
isolation. Culture medium was removed and 1ml of reagent was added and mixed well 
per sample. For each 1ml of RNAzol® RT used, 0.4ml of water was added to the lysate 
for homogenization. The resulting mixture was shaken vigorously for 15 seconds and 
stored at room temperature for 15 minutes. Next, samples were centrifuged at 12,000g 
for 15 minutes. Around 1ml of the supernatant was transferred to a new tube, leaving 
a layer of the supernatant above the DNA/protein pellet. RNA was then precipitated 
by mixing the transferred supernatant with 0.4ml of 75% ethanol (v/v). Samples were 
stored for 10 minutes at room temperature and centrifuged at 12,000g for 8 minutes. 
RNA precipitate forms a white pellet at the bottom of the tube. This is diluted with 
- 48 - 
 
nuclease-free water to form the purified RNA samples. cDNA was then synthesized 
using the High-Capacity cDNA Reverse Transcription Kit (Thermo). A reverse 
transcriptase (RT) master mix was prepared for all the RNA samples on ice. This 
master mix contains 10X RT Buffer, 25X dNTP Mix (100mM), 10X RT Random 
Primers, MultiScribeTM Reverse Transcriptase, RNase inhibitor and nuclease-free 
water. Equal volume of RNA sample was mixed with the RT master mix and left on 
ice. The thermal cycling conditions used starts with 10 minutes at 25oC followed by 
120 minutes at 37oC. Lastly samples were subjected to 85oC for 5 minutes before 
storing them at -20oC before further analysis. qRT-PCR was performed using the 
StepOnePlus instrument (Thermo) with pre-designed TaqMan® Gene Expression 
Assays (Thermo): EPAS1 (Hs01026149_m1), CXCR4 (Hs00607978_s1), VHL 
(Hs03046964_s1) and TBP (Hs00427620_m1). The PCR reaction mix was prepared 
consisting 20X TaqMan® Gene Expression Assays, 2X TaqMan® Gene Expression 
Master Mix, cDNA template and RNase-free water. 96-well plates were loaded with 
the reaction mix for triplicates of each sample. Control wells were also prepared 
consisting only the mix without any cDNA template. Signal was quantified using the 
double delta Ct method and normalized to TBP as the housekeeping control.  
 
Western Blotting. Whole-cell extract was trypsinised from 10cm dishes and pellets 
were washed with 1x PBS twice before the protein extraction step. Cells were lysed in 
50μl of RIPA buffer (Sigma-Aldrich, Life Science) supplemented with 1/100 protease 
inhibitors cocktail for 30 minutes on ice to extract protein. Supernatant was collected 
into microcentrifuge tubes. Protein for each sample was quantified in duplicates in 96-
well plates using the PierceTM BCA Protein Assay Kit (ThermoScientific) that includes 
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a set of standards as reference. Quantification was done based on absorbance levels 
at 562nm wavelength under the plate reader. The appropriate volume was calculated 
for 50μg of each sample. Prepare SDS-PAGE gels to load samples in. An 8% 
acrylamide resolving gel was usually used that is made up of 7.68ml of 1.5M Tris pH 
8.8, 320μl of 10% SDS, 5.3ml of 30% bisacryl/acryl, 150μl of 10% (w/v) APS, 15μl of 
TEMED and 6.5ml of H20. This is then stacked with a standard stacking gel. Samples 
were then prepared using the protein extract. 50μg of protein were mixed with 5x 
concentrated loading buffer and 1/20 β-mercaptoethanol. Samples were then boiled 
for 5 minutes at 95oC and spun for 1 minute at 10000 rpm at 4oC. Loaded samples 
into wells of gel along with a protein ladder. Filled tank with running buffer and ran at 
80V until samples passes through the stacking gel. This is followed by a 100V for the 
remainder of the gel running process. Gels were usually running for around 2 hours. 
When complete the protein samples in the gel were then transferred onto a PVDF 
membrane. This transfer process involves the building of a ‘sandwich’ cassette 
consisting of sponges, filter papers, gel and the 100% methanol soaked PVDF 
membrane. This ‘sandwich’ ran at 150V and 400mA in a tank filled with transfer buffer 
along with a magnetic stirrer at the bottom and an ice pack to keep it cool. Transfer of 
proteins were checked by staining the membrane with Ponceau S stain for 5 minutes 
and then de-stained in PBS-T solution. The membrane was then blocked for 1 hour in 
milk. This is followed by an incubation with primary antibodies diluted in milk overnight. 
Following a washing step, the secondary antibody diluted in milk was added on the 
membrane and incubated on a shaker for 1 hour followed by another washing step. 
Roughly around 4ml of Pierce ECL substrate (Thermo) was added on the membrane 
and left for 5 minutes. Films were used to visualise protein bands. Primary antibodies 
for HIF2A (Novus Biologicals NB100-122), FLAG (Sigma #F3165), VHL (BD 
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Biosciences #564183) and β-actin (Sigma #A1978) were used. Secondary antibodies 
were polyclonal goat anti-mouse immunoglobulins/HRP (Dako) and polyclonal goat 
anti-rabbit immunoglobulins/HRP (Dako).  
 
Lentiviral Transduction. Lentivirus was produced by transfecting HEK293T cells with 
the psPAX2 and pMD2.G viral packaging plasmids along with the lentiviral plasmid 
using FuGENE® 6 Transfection Reagent (Promega E269A). Before the use of the 
transfection reagent, it was allowed to reach room temperature and mixed by 
vortexing. Virus production was carried out in 6-well plates. For a 3:1 FuGENE® 6 
Transfection Reagent:DNA ratio, 6μl of FuGENE® 6 Transfection Reagent was mixed 
with pre-warmed medium and left at room temperature for 5 minutes. Next, 2μg of 
plasmid DNA was added to the FuGENE® 6 Transfection Reagent/medium and mixed 
immediately. This reaction mix was incubated at room temperature for 15 minutes. 
300μl of the reaction mix was added to each well of a 6-well plate containing cells in 
growth medium. Each well was mixed by pipetting for 10 seconds. Cells were then left 
in the incubator for 48 hours. Viral supernatant was harvested 48 hours after 
transfection and filtered through a 0.45 mm PVDF syringe filter. Cells were transduced 
with the virus along with 8μg/ml of polybrene (Milipore) for 24 hours. The number of 
positive cells were assessed through FACS analysis.   
 
Nucleofection. Cells to be nucleofected were counted using the cell counter to find 
the volume needed for 106 cells per condition. These cells were centrifuged at 90xg 
for 10 minutes at room temperature. Supernatant was removed completely to obtain 
pellets of the cells as samples to be transfected. Tubes of mixes containing the 
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respective plasmids to be transfected were prepared in 100μL of room-temperature 
AMAXA Nucleofector solution for each sample. The DNA mixes were combined with 
their respective cell pellet sample to form a cell/DNA suspension. These suspensions 
were then transferred into certified cuvettes. Nucleofector programs were chosen 
based on optimization experiments carried out for each cell line. The cuvettes with the 
cell/DNA suspensions were nucleofected and immediately after 500μl of pre-
equilibrated culture medium was added to the cuvette. The entire suspension was 
gently transferred into 6-well plates containing fresh media. Cells were then incubated 
at 37oC until analysis. This method of transfection was applied to both 786-0 and 786-
M1A ccRCC cells, whereby the two best nucleofector programs were the T-20 and the 
X-05 programs.  
 
Lipofectamine 2000 Transfection. Transfection was carried out in nearly confluent 
cells (90-95%) seeded in 6-well plates using Lipofectamine 2000 (Invitrogen). Plasmid 
DNA mix was prepared using varying ratios to yield a total of 4μg of DNA and these 
were diluted with OPTI-MEM® I Reduced Serum Medium to give a total of 250μL of 
DNA/OPTI-MEM mix. A mix of 10μL of Lipofectamine and 250μL of OPTI-MEM® I 
Medium were prepared per well and left at room temperature for 5 minutes. For each 
well of a 6-well plate, 250μL of DNA/OPTI-MEM and 250μL of Lipofectamine/OPTI-
MEM mix was produced. This final mix was incubated at room temperature for 20 
minutes before 500μL of the respective mix was added into each well along with 1.5mL 
of fresh media. Media was changed in transfected wells the following day. This method 
of transfection was applied for the RFX631, UOK101 and A498 ccRCC cell lines.  
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MTT assay for cell viability analysis under SCR7 treatment. Cell viability of 786-
O, 786-M1A, UOK101 and RFX631 were determined by MTT assay (ThermoFisher 
Scientific, no. M-6494). A 12mM MTT stock solution was prepared by adding 1ml of 
sterile PBS to one 5mg vial of MTT. Mixed by vortexing until dissolved. Optimal cell 
counts were determined for each cell line to be seeded in a 96-well plate to reach 
optimal population throughout the course of SCR7 treatment. Cells were then grown 
in the presence of SCR7 (0.01, 0.1, 1 and 10μM) for 24 or 96 hours in their respective 
96-well plates. At each time point 10μL of MTT reagent was added to each well and 
left to incubate at 37oC for 2 to 4 hours until purple precipitate is visible. Then 100μL 
of detergent reagent was added per well and left at room temperature in the dark for 
2 hours. Absorbance was recorded using a plate reader at 570 nm. At least three 
independent technical repeats were done for each experiment. 
 
SCR7 drug treatment for HDR-based reporter knock-in. The SCR7 drug was 
diluted in DMSO at 10mg/ml. As the testing of different SCR7 concentrations did not 
affect the cell viability of the four cell lines (786-0, 786-M1A, UOK101 and RFX631) as 
seen above, 10μM of SCR7 was applied to all cells at the same time as transfection 
of the plasmids needed for CRISPR-Cas9-based HDR knock-in. The day after 
transfection the media was changed and SCR7 was re-administered and left for 4 
days. Following SCR7 treatment, cells were washed off the drug by replacing with a 
fresh media and antibiotic selection process commenced.  
 
Sanger Sequencing. All purified samples were sent for sequencing using the 
Mix2Seq Kit (Eurofins). Samples of plasmid DNA templates consisted of 15uL purified 
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DNA with around 50-100ng/μL concentrations. Primers with a concentration of 
10pmol/μL (10μM) were added with a volume of 2μL. Total volume of the premixed 
sample (DNA + Primer) was at least 17μL. Sequencing analysis was done using the 
Basic Local Alignment Search Tool (BLAST) or through the use of SnapGene. 
 
Minicircle Production. A simplified procedure was based on the protocol in Kay et 
al.212. Firstly, the minicircle parental plasmid (pMC.BESPX-MCS2 (System 
Biosciences MN100B-1)) carrying the transgene of interest was cloned and 
transformed using a normal competent E. coli following a standard protocol. The 
colonies produced were inoculated and plasmid DNA was prepared followed by a 
restriction diagnostic digest to determine the correct plasmid with the transgene. The 
ZYCY10P3S2T competent cell was then transformed with this minicircle parental 
plasmid carrying the transgene of interest. Colonies produced from this second 
transformation was then picked and inoculated in 2ml of LB containing kanamycin 
(50μg/ml) at 37oC with shaking at 250rpm. An overnight culture was then created by 
combining 100ul of this culture with 100ml Terrific Broth (TB) containing kanamycin 
(50μg/ml) and incubated with shaking at 37oC and 250rpm. After an overnight culture 
of 16-18 hours, the OD600 reading was measured to be between 4 to 5, pH 6.5. For 
a 100ml overnight culture, a Minicircle Induction Mix comprising 100ml LB, 4ml 1N 
NaOH and 100μL 20% L-arabinose was prepared. The Minicircle Induction Reaction 
was casted by combining the Minicircle Induction Mix with the overnight culture and 
incubated at 32oC with shaking at 250rpm for 5 hours. The resulting bacteria culture 
was pelleted and the minicircle was isolated using a normal MaxiPrep plasmid DNA 
extraction kit. Unlike the usual manufacturers protocol of the DNA extraction kit, the 
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volumes of buffers used were doubled for each minicircle extracted. The purified 
product was tested to ensure no parental plasmid contamination.  
 
HDR Plasmid Template Cloning. Step-wise cloning into truncated pcDNA3.1(-) 
(adapted from Thermo #V79520) plasmid backbone, that was developed by David 
Hoffmann for the lab, was carried out. This truncated plasmid was removed of its CMV 
enhancer and promoter preceding the multiple cloning site. Homology arms that spans 
the site of integration in the EPAS1 gene was PCR amplified from genomic DNA 
obtained from ccRCC cell lines. Both 5’ and 3’ homology arms that flanks the 
fluorescent construct is around 800-1000bp in length. Fluorescent reporter gene in the 
construct is an mCherry fluorescent gene that was PCR amplified from pU6-
sgCXCR4-2 plasmid (Addgene #46917)209. The forward primer of the mCherry PCR 
amplification included a T2A sequence to produce a T2A-mCherry fragment. 
Hygromycin resistant gene for selection purposes for the construct was amplified from 
pRetroX-Tight-Hygro (Clontech #631034) plasmid that included a PGK promoter to 
form a PGK-HygR fragment. The homology arms, T2A-mCherry fragment and PGK-
HygR fragment was amplified along with restriction enzyme sites on each end that 
complements the multiple cloning site of the pcDNA3.1(-) plasmid. Each cloning step 
for each fragment was accompanied by a diagnostic digest step to ensure the right 
construct was inserted at the right site in the plasmid. Once the whole construct was 
cloned in, the plasmid was sent for sequencing to ensure the plasmid template was 
constructed precisely.  
 
- 55 - 
 
Fluorescence-Activated Cell Sorting (FACS). Cells were trypsinized, pelleted and 
resuspend in fresh media in FalconTM Round-Bottom Polystyrene Tubes at a volume 
of 1ml or less. These cells were analysed for fluorescence on an LSR Fortessa (BD 
Biosciences). Single cells were detected on the basis of FSC-A, FSC-H and SSC-A. 
mCherry (561nm/610nm), EGFP (488nm/509nm), and BFP (383nm/445nm) 
fluorescence was measured. Cell sorting was performed on an Influx cell sorter (BD 
Biosciences) using the same settings as described above. Single cells were sorted 
onto individual wells of a 96-well plate containing cancer cell-conditioned RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), penicillin (100 U ml-1) and 
streptomycin (100 μg ml-1). FlowJo software was used to analyse data obtained.  
 
Immunofluorescence. Cells grown on coverslips in 6-well plates were washed with 
PBS and incubated with 4% PFA in PBS for 10 min at room temperature (RT). Fixative 
was aspirated and cells were rinsed three times. In 1X PBS for 5 minutes each. Cells 
were then permeabilized with 0.5% Triton X-100 (Sigma). A drop of ProLong Diamond 
Antifade Mountant with DAPI (Life Technologies) was placed on microscope slides 
and coverslips with cells were mounted on them. After 5 minutes of incubation at RT, 
imaging was done on a Leica TCS SP5 confocal microscope.  
 
CRISPRi-based inhibition experiments and sgRNA enrichment analysis. ccRCC 
cells to be used for in this experiment were transduced with a pHR-SFFV-dCas9-BFP-
KRAB (Addgene #46911)209 plasmid to constitutively express a catalytically inactive 
dCas9. After isolation of a pooled of positively transduced dCas9 cells, they were 
transduced with HIF2A-targeting constructs (iHIF2A-1, iHIF2A-2, iHIF2A-3, Scramble) 
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cloned into pKLV-U6gRNA(BbsI)-PGKHyg2AEGFP (adapted from Addgene 
#50946)208. These transduced cells were then selected for with the selection marker. 
Positive cells were then analysed using a combination of Western blotting, qRT-PCR 
and FACS analysis to measure the effects of targeting HIF2A for mutation and what it 
does to the fluorescence levels of mCherry. The same set of reagents were also used 
in the sgRNA enrichment analyses of H2AmC systems whereby sgRNA abundance 
was visualized through FACS analysis for EGFP fluorescence.  
 
CRISPR-Cas9-based sgRNA enrichment experiments. ccRCC cells to be used for 
this experiment was transduced with the Lenti-Cas9-EGFP (adapted from Addgene 
#52962)210 plasmid. Transduced cells were then sorted for pools and single cell clones 
based on their EGFP fluorescence. Pooled sorted cells were analysed for their 
presence of FLAG-Cas9 protein through Western blotting analysis. The best single 
cell derived clones of the transduced cells were selected based on the highest 
expressing EGEP fluorescence. The selected clones were then transduced into pKLV-
U6gRNA(BbsI)-PGKpuro2ABFP (Addgene #50946)208 plasmids containing single 
sgRNA constructs targeting HIF2A for mutation (sgEPAS1-1, sgEPAS1-5, CTRL). 
Transduced Cas9-expressing cells were then analysed for the effects of a targeted 
HIF2A mutation on the mCherry fluorescence as well as the enrichment of the EGFP-
expressing HIF2A-targeting sgRNA constructs within the mCherry population.  
 
sgRNA Library Production. The entire transcription factor (TF) library was produced 
by Saroor Patel, a postdoctoral researcher in the lab. Genes encoding known 
transcription factors were identified from previously curated list213. The TF library also 
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contains 100 non-targeting control sgRNAs214. The sequences for the sgRNAs were 
taken from Wang et. al.214 with seven sequences selected for each gene. Oligos were 
ordered from Custom Array Inc. Oligos were amplified and cloned into pKLV-
U6gRNA(BbsI)-PGKHyg2AEGFP (adapted from Addgene #50946)208 by Gibson 
assembly215.  
The chromatin factor library was partly generated by Saroor Patel. Genes encoding 
known or putative chromatin factors were identified from previously curated lists216–219. 
The library also contained additional control genes, such as known essential genes, 
as well as 100 non-targeting control sgRNAs214. The sequences for the sgRNAs were 
taken from Wang et. al.214 with nine sequences selected for each gene. Oligos were 
ordered from Custom Array Inc. Oligos were amplified and cloned into pKLV2-
U6gRNA5(BbsI)-PGKpuro2ABFP-W (Addgene #67974)179 by Gibson assembly215.  
The library production steps, that were handled by Saroor Patel, involved firstly the 
PCR amplification of the Custom oligo pool ordered from Custom Array Inc. Each oligo 
is a 109 mer with sgRNA target sequence. PCR conditions were also optimized for the 
oligo pools. This involved optimizing the temperature gradient and different dilutions 
of samples. PCR was carried out using an Accuprime Pfx Supermix. Purification of 
PCR pools involved mixing all the separate reaction together and purifying with the 
columns from MinElute PCR Purification Kit (Qiagen #28004). Next cloning with 
Gibson assembly was carried out using 30bp-overlapping primers. The respective 
backbone for library cloning was prepared by digesting them with BbsI and running 
them on an agarose gel to inspect for successful digestion. The Gibson Assembly 
Master Mix (New England Biolabs #E2611) was used for Gibson assembly reactions. 
The MegaX DH10B T1 Electrocomp Cells (Invitrogen #6400-03) was used for library 
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cloning. The electroporated bacteria/DNA mixture was then plated on 25cm plates with 
LB-Amp Agar and incubated at 37oC. Some colonies were picked and sent for 
sequencing to see if it contains multiple sgRNA fragments.  
 
Pooled CRISPR-Cas9 Screening. The lentiviral sgRNA library was produced using 
HEK293T cells as described above. H2AmC and M1CXmC cells were first transduced 
with the lentiviral library at varying concentrations to determine the amount needed for 
a MOI of ~0.11. The respective number of cells transduced for each screen carried 
out in this project is outlined in their respective results section (Section 4.3.1.1, Section 
4.3.2.1, Section 5.4.1.1.1). Cells were transduced with the lentiviral library at a low 
MOI, leading to ~10% positive cells and ensuring a >1000x representation of the 
library. Virus was removed the following day. Puromycin or hygromycin treatment was 
carried out depending on the type of sgRNA library used. For the TF screen the lowest 
10% and lowest 1% of mCherry population were isolated by FACS from the H2AmC 
cells. Only the lowest 10% of the mCherry population from the chromatin regulator 
screens with H2AmC cells and M1CXmC cells were isolated by FACS. A total of 120 
million cells were transduced with the TF library and the screen went on for around 4 
weeks post-transduction before all the samples were collected. The lowest 10% 
mCherry population was collected 2 weeks post-transduction and the lowest 1% 
mCherry population was collected 4 weeks post-transduction. A total of 120 million 
cells were transduced with the chromatin library and the screens went on for around 
3 weeks post-transduction for the screens in both H2AmC systems and M1CXmC 
systems before the lowest 10% mCherry population was collected. The cells were 
pelleted along with their respective unsorted controls. DNA was extracted and 
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amplified for the region containing the sgRNAs that amounted to a genomic band of 
274bp. The DNA extraction step was carried out using the QIAamp DNA mini kit 
(Qiagen) following manufacturers protocol. For the amplification of the guide RNA 
sequence, primers that have tails for Illumina sequencing and an index to barcode the 
DNA was used. This is followed by a phenol extraction step followed by purification 
using an Agencourt AMPure XP beads purification protocol. Purified samples were 
pooled and quantified with Qubit before sending for Illumina sequencing in a 
HiSeq4000 instrument.  
All sequencing results were aligned using Bowtie by Sakari Vanharanta and 
normalised to one million reads. Normalised counts of less than five were removed 
from the analysis. The fold change enrichment for the TF screen were calculated for 
each sgRNA in H2AmC cells by calculating the fold change of the lowest 10% sorted 
population compared to their respective unsorted control and by calculating the fold 
change of the lowest 1% sorted population compared to their respective lowest 10% 
sorted population. The fold change enrichment for the chromatin screens were 
calculated for each sgRNA in both H2AmC and M1CXmC cells by calculating the fold 
change of the sorted samples compared to their respective unsorted control sample. 
Next, the median of all the remaining sgRNAs per gene in each system was calculated. 
This data was normalised to obtain a z-score for each gene. The average of the 
normalised median enrichment for each gene was then calculated between the two 
systems. For each gene, empirical P-values were calculated using a resampling-
based method with 1000 permutations and multiple testing correction using FDR. 
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Statistical Analysis. Statistical analyses were conducted in R and Microsoft Excel. 
All the P-values stated in the thesis that were lower than 0.05 were considered 
statistically significant. For the TCGA data analysis, a Wilcoxon rank-sum test was 
used in the analysis. This was carried out by comparing the TPM values of ccRCC 
with the normal kidney values. A comparison was also carried out between the ccRCC 
values with the collective values of all the other types of cancer. For qRT-PCR 
experiments three independent experiments were shown, each of which is the average 
of three technical replicates, unless stated otherwise in the figure legends. A standard 
student’s T-test was used for the analysis of all qRT-PCR experiments where *P<0.05, 
**P<0.01, and ***P<0.005. To determine the correlation of all sgRNA counts observed 
between two systems for all the screens, a Pearson Correlation Coefficient (PCC) was 
calculated. This coefficient was calculated by plotting all the sgRNA counts for each 
system against each other and measuring the coefficient value of one system to the 
other. Positive coefficient values were expected of sgRNA counts in the screens and 
values greater than 0.6 has a good strength of association between the two systems. 
For significance tests of potential hits in all the screens, a 1000x permutation analysis 
was applied to obtain an empirical P-value. The permutation analysis was carried out 
by resampling the original sgRNA counts/million reads for 1000 times and running the 
entire analysis again exactly the same as the original data. The empirical P-value was 
obtained by comparing the original data (observed data) to the expected permutated 
data. This P-value was also false discovery rate (FDR)-corrected. 
Data availability. The TCGA data set was downloaded from the TCGA data portal 
at https://tcga-data.nci.nih.gov/. The datasets and reagents generated during the 
current study are available from the corresponding author on reasonable request.  
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Chapter 3: Development of HIF2A Endogenous Reporter 
Systems 
3.1 Introduction 
 The mechanism of HIF2A protein stabilization in ccRCC has been well 
characterised through the loss of VHL in the VHL/HIF pathway. It was shown that the 
absence of functional pVHL results in the inability to recognise hydroxylated forms of 
HIF2A for proteasomal degradation. This results in the loss of control of the gene 
expression program downstream of HIF2A which leads to the progression of 
ccRCC102. Despite numerous evidence on the relevance of the VHL/HIF2A pathway 
for ccRCC growth in vivo, targeting HIF2A directly or via VHL restoration does not 
have an obvious growth phenotype in tissue culture systems87. Furthermore, 
differential sensitivities were observed in HIF2A antagonist treatments of human 
ccRCC tumorgrafts153. Hence, an investigation has to be done on alternative 
Figure 9.  TCGA data analysis of HIF2A mRNA expression in ccRCC compared to 25 
different tumour types and normal kidney. P-value by Wilcoxon rank sum test. TPM, 
transcripts per million. 
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regulatory mechanisms that may work together with the VHL/HIF2A pathway in 
maintaining ccRCC progression to discover novel therapeutic targets.  
Analysis of RNA-seq data in the lab by Sakari Vanharanta from 26 different 
tumour types from the TCGA cohort showed that HIF2A mRNA was highly expressed 
in ccRCC when compared to other tumour types (Figure 9). This elevation in HIF2A 
mRNA expression is also seen in ccRCC when compared to normal kidney. With VHL 
mutations being remarkably specific for ccRCC with around 50% of mutation 
frequency observed compared to other tumour types220,221, this data suggested the 
possibility that high HIF2A mRNA expression levels in ccRCC may modulate the 
potential at which VHL loss promotes tumorigenesis.  
 
3.2 CRISPR-Cas9 genome engineering of EPAS1 
3.2.1 HDR Plasmid Template Design 
To monitor the endogenous mRNA expression of HIF2A, a reporter construct 
expressing a fluorescent marker was integrated into the coding sequence of EPAS1. 
For a precise knock-in of the reporter construct into the gene without affecting its 
endogenous mRNA expression, a homology-directed repair (HDR)-based integration 
method following CRISPR-Cas9 double stranded break was used (Figure 10). This 
method utilises a plasmid template carrying the transgene of interest with homology 
arms (HA) complementary to the site of integration195. To introduce a large construct, 
homology arms of around 800-1000bp in length was used that has been proven to 
result in efficient transgene integration196. The location of integration within the EPAS1 
gene was determined to minimise the effects on the function of the endogenous gene 
but still within the coding sequence to express the fluorescent gene from the same 
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EPAS1 promoter. Hence, the target site was at the very end of the last exon sequence, 
Exon 16, just before the STOP codon (Figure 10). A protospacer adjacent motif (PAM) 
sequence is present within this target site making it ideal for CRISPR-Cas9 mediated 
double-stranded break. Studies have shown that Cas9 induce double stranded breaks 
around 3-4 nucleotides upstream of the PAM sequence174.  
Within the construct lies a fluorescent reporter gene and an antibiotic selection 
marker that are both flanked by the homology arms (HA) (Figure 10). A number of 
ccRCC cell lines in the lab especially the metastatic derivatives express a green-
fluorescent protein (GFP)-luciferase reporter, therefore any other fluorescent gene 
was considered for the design of the construct. An mCherry fluorescent gene was 
chosen as it is the most photostable red monomer fluorescent protein available and 
Figure 10.  Schematic of CRISPR-Cas9-based knock-in strategy of an mCherry 
fluorescent gene into the exon 16 of EPAS1. Plasmid template consists of an mCherry 
fluorescent gene with a hygromycin selection marker that are flanked by homology arms 
(HA). Sequencing primers used for genomic and cDNA amplifications are shown. 
sgRNA, single guide RNA. UTR, untranslated region. HygR, hygromycin resistant gene. 
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matures rapidly that bodes well with the intention to visualise changes in fluorescence 
due to changes in gene expression222,223. Other brighter fluorescent proteins within the 
red class are of larger size, that might affect the efficiency of reporter construct 
integration within the genome. Moreover, a number of developed reporter systems 
have utilised mCherry as a fluorescent marker223. A hygromycin selection marker was 
chosen for the construct as most follow-up experiments would require a puromycin-
based selection. The inclusion of this selection marker would assist in isolating positive 
clones from the engineered cells. Moreover, having it driven by its own PGK promoter 
would potentially be less detriment to the endogenous EPAS1 gene as it is expressed 
as its own transcript separate to EPAS1-mCherry. Finally, the design of the donor 
template is such that the homology arms flank both sides of the integration site that 
results in the abrogation of the sgRNA target sequence once the construct is 
integrated, thus preventing further double stranded breaks within the same site.  
 The mCherry fluorescent gene fragment was amplified with a T2A self-cleaving 
peptide after the EPAS1 gene (Figure 10). These peptides are 18-22 amino acid long 
viral oligopeptides that mediate separation of polypeptides during translation. T2A 
refers to the thosea asigna virus 2A viral genome224. As the fluorescent construct is 
devoid of a promoter sequence, it relies on the promoter of EPAS1 for its expression. 
Furthermore, such a sequence is required to ensure single expression of a gene, i.e. 
one mRNA, that will then produce two proteins without affecting the expression of the 
endogenous protein. Another method of expressing more than one protein from a 
single promoter involves the use of an internal ribosome entry site (IRES). This internal 
initiation can be seen in some viral and eukaryotic cellular mRNAs that is generally 
independent of recognition of the 5’-mRNA ends. Direct recruitment of the 40S 
ribosomes occurs within the vicinity of the initiation codon225. Several developed 
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endogenous reporter systems also utilize IRES to separate two genes from each other 
within a construct199,226. Although proven functional, a number of limitations arise from 
this element, which include their large size and variability in expression227,228. 
Therefore, an IRES sequence might produce differing amounts of encoded proteins 
that varies depending on the target cell. On the other hand, the T2A self-cleaving 
peptide is a good candidate instead of the IRES sequence due to its small size and 
high cleavage efficiency between genes upstream and downstream of the 2A 
peptide228. Hence, both HIF2A and mCherry will be expressed at equal amounts 
through a mechanism of ribosomal skipping, due to the highly conserved sequence 
GDVEXNPGP at the C-terminus229.  
The backbone for the plasmid template has to be one that is suited for cloning. 
This was chosen to be the mammalian expression vector, pcDNA3.1(-) plasmid. With 
no intention of enabling the construct to express until successful integration occurs, 
the plasmid’s CMV enhancer and promoter preceding the multiple cloning site (MCS) 
Figure 11. HIF2A mRNA expression and protein levels in 18 ccRCC cell lines. (a) qRT-
PCR analysis of EPAS1 mRNA expression levels in ccRCC cells compared to HEK293T 
cells as control. This was carried out in triplicates of technical repeats with a single 
biological repeat. (b) Western blot analysis of HIF2A protein levels in ccRCC cells 
compared to HEK293T cells as control. B-actin act as a loading control. This represents 
single biological repeat. 
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was removed. Moreover, the neomycin/kanamycin resistant gene of the plasmid was 
also removed to strip the plasmid to its bare essentials, generating a truncated version 
of the original plasmid (pcDNA3.1(-) truncated) which was generated by a student, 
David Hoffmann, for the use of the lab.  
 
3.2.2 HDR-assisted knock-in of mCherry fluorescent reporter 
 HDR-based knock-in efficiencies have shown to be cell line specific with 
efficiencies high in cell lines from the human embryonic kidney, HEK293T197. In cancer 
cell lines, HDR efficiencies vary203. For this reason, based on RNA-seq analysis in the 
Figure 12.  MTT assays to measure cell viability when treated with SCR7. Different 
concentrations of SCR7 (0.01, 0.1, 1, 10μM) were added to a) 786-O, b) RFX631, c) 786-
M1A and d) UOK101 cells and incubated for 24 hours and 96 hours respectively. Cell 
viability was measured as a percentage over the reference cells where no drug was 
administered. This was carried out in triplicates of technical repeats with a single 
biological repeat. 
RFX631 
SCR7 concentration (µM) SCR7 concentration (µM) 
SCR7 concentration (µM) SCR7 concentration (µM) 
a b
c d
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lab, ccRCC cell lines showing an mRNA expression level of HIF2A was further 
inspected. This data was corroborated with the analysis carried out on the mRNA 
expression levels and protein levels of HIF2A in the inspected cell lines (Figure 11). 
Without knowing which cell lines would work best for HDR-based knock-in strategy 
and based on the availability and frequency of use of the ccRCC cell lines in the lab, 
four cell lines were chosen for subsequent experiments that included the RFX631 and 
UOK101 cells as well as two well studied renal cancer cell lines (786-0 and its 
metastatic derivative, 786-M1A).  
 The activity of the HDR DNA damage repair mechanism can be hindered by 
the non-homologous end joining (NHEJ) repair pathway that occurs in tandem when 
a double stranded break occurs. Additionally, as NHEJ repair pathway function is not 
affected by the cell cycle phase unlike HDR, NHEJ occurs predominantly compared 
to HDR230. To reduce the effects of NHEJ repair mechanism and maximise possibility 
of HDR-based repair, a drug that inhibits the NHEJ pathway was used, called SCR7. 
Specifically, it targets DNA ligase IV, which is a key enzyme in the NHEJ pathway that 
results up to 19-fold increase in the efficiency of HDR-mediated genome editing231. 
The cell lines were also tested with different concentrations of the drug (0.01, 0.1, 1, 
10μM) with varying times of incubation (24 and 96 hours) to test for any effects on cell 
viability (Figure 12). For this purpose, an MTT assay was performed that measures 
the cell viability by assessing cell metabolic activity through the reduction of 
tetrazolium salts. Cell viability was measured as the percentage over the reference 
cells where no drug was administered. The collected findings showed no significant 
detriment to the cell viability of all four cell lines tested (Figure 12). 
 Transfection of the ccRCC cell lines was carried out with the plasmid template 
carrying the mCherry fluorescent construct, a plasmid backbone with the sgRNA target 
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sequence and a BFP fluorescent plasmid transfection control. Optimization of co-
transfection conditions with Lipofectamine for these cell lines were achieved through 
the testing of different ratios of Lipofectamine to DNA concentration while different 
programs were tested for nucleofection (Figure 13). Transfection condition using 10μl 
of Lipofectamine was chosen for both RFX631 and UOK101 cells to maximise the 
percentage of positive cells as well as keeping cell death to a minimum. Nucleofection 
program of T-20 was picked for both 786-0 and 786-M1A cells. An SCR7 concentration 
of 10μM was applied to all cells throughout the transfection process and maintained 
4-days post-transfection with hopes of maximising integration potential. Following 
SCR7 treatment, cells were selected for hygromycin resistance. Out of the four cell 
lines transfected, only UOK101 cells survived the selection process and were removed 
of all drugs to recover and expand. 
Cell Line Transfection Condition Cell Viability Positive cells 
(%) 
RFX631 4ul Lipo (1ug DNA: 1ul Lipo) ~80% confluent, few death 1.9% 
10ul Lipo (1ug DNA: 2.5ul 
Lipo) ~60% confluent, moderate death 
3.9% 
20ul Lipo (1ug DNA: 5ul Lipo) ~40% confluent, more death 4.5% 
UOK101 4ul Lipo (1ug DNA: 1ul Lipo) 
All confluent wells, 
increasing cell death with 
more Lipofectamine 
0.9% 
10ul Lipo (1ug DNA: 2.5ul 
Lipo) 2.7% 
20ul Lipo (1ug DNA: 5ul Lipo) 2.3% 
 
Cell Line Program Cell Viability Positive cells (%) 
786-M1A / 786-0 T-20 ~40% confluent in 6-well plates 52.1% 
X-05 ~50% confluent in 6-well plates 34.7% 
Figure 13.  Optimization of transfection conditions in ccRCC cell lines. Lipofectamine 2000 
transfection methods were used for RFX631 and UOK101 cells. Nucleofection methods were 
used for 786-0 and 786-M1A cells. Positive cells based on BFP fluorescence measured 
through FACS. Cell viability estimated under the microscope.  
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3.3 Analysis of HIF2A mCherry single cell clone system 
3.3.1 Validation of mCherry integration in EPAS1 locus 
 Transfected cells were sorted for mCherry positive fluorescence into single cell 
clones (Figure 14). The generation and analysis of single cells allows for a 
homogenous population of cells to be isolated that carries the same integration, thus 
uniform expression of mCherry fluorescence232. This eliminates possible variability in 
mCherry fluorescence that would be encountered in a bulk population of cells.  Even 
with the high specificity of the HDR-based CRISPR-Cas9 knock-in mechanism, the 
Figure 15. (a) Genomic amplification of the HIF2A-mCherry integration site in single-
cell derived clones. WC, water control. GC, genomic control. (b) cDNA amplification 
of the HIF2A-mCherry integration site. WC, water control. GC, genomic control. The 
respective genomic and cDNA primers are shown in Figure 10. 
Figure 14. Single cell sorting of transfected UOK101 cells. Gating of positive mCherry 
cells was determined based on parental control. 
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mCherry fluorescent construct could still be integrated anywhere else in the coding 
sequences of the genome, hence expressing mCherry to produce false positive 
clones. Primers were therefore designed to amplify the integration site within the 
EPAS1 gene to determine clones with the right integration, which is highlighted in 
Figure 15. PCR amplification of the transfected cells will either yield a band of 3kb in 
size proving positive integration of the construct compared to a 1kb band of the wild-
type genome. Presence of both bands would highlight single allele integration of the 
construct.  Single cell derived clones of UOK101 cells amplified for the integration site 
highlighted 3 out of 9 clones with positive integration, henceforth referred to as HIF2A-
mCherry-single-cell-clone 1-3 or H2AmC1-3 (Figure 15a). A clear single 3kb band can 
Figure 16.  Sequencing of integration sites. (a) Sanger sequencing of the HIF2A-mCherry 
integration sites in H2AmC1 cells. (b) Sanger sequencing of the HIF2A-mCherry integration 
sites in H2AmC2 cells. (c) Sanger sequencing of the HIF2A-mCherry integration sites in 
H2AmC3 cells. 
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be seen for all 3 clones that translates to possible integration in both alleles of EPAS1 
(Figure 15a). Complementary finding was seen when cDNAs of the three clones were 
PCR amplified with a different set of primers that includes part of the last exon and the 
mCherry construct (Figure 10), yielding a single 500bp band further proving positive 
integration of the mCherry construct (Figure 15b). The bands obtained from the 
genomic amplification of the integration sites for all three H2AmC clones were purified 
and sequence verified to show precise integration with no mutations observed (Figure 
16).  
Fluorescence was inspected to determine if the mCherry construct integrated 
is expressed. All three H2AmC clones were measured for mCherry fluorescence 
through FACS analysis and each clone showed positive fluorescence, which is around 
double the intensity when compared to the parental control UOK101 cells (Figure 17a). 
Figure 17.  (a) FACS analysis of mCherry fluorescence in the three H2AmC clones 
compared to the parental UOK101 cells. (b) Confocal microscopy images of mCherry 
fluorescence in the three H2AmC clones compared to the parental control. DAPI in blue, 
mCherry in red. 
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To validate the mCherry expression further, confocal microscopy was used on the 
H2AmC clones that clearly showed the presence of red mCherry fluorescence when 
compared to the control cells (Figure 17b). These results show that three single cell 
clones were derived from UOK101 cells with an expressed mCherry fluorescent gene 
integrated in the EPAS1 gene, which would be candidates for the HIF2A screening 
system.  
 
Figure 18.  (a) Schematic of CRISPRi-based inhibition of reporter activity. RNAPol, RNA 
Polymerase II. KRAB, Kruppel associated box. (b) Relative HIF2A mRNA levels in H2AmC2 
and H2AmC3 dCas9 cells transduced with HIF2A-targeting sgRNAs or a non-targeting 
control. *P < 0.05, **P < 0.01, ***P < 0.005, n.s., non-significant. P-value by Student’s t-test. 
Analysis was based on three technical replicates for each of three biological repeats. (c) 
Western blot analysis of H2AmC2 and H2AmC3 dCas9 cells transduced with HIF2A-
targeting sgRNAs or a non-targeting control. B-actin acts as a loading control. Analysis was 
carried out for two biological repeats. 
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3.3.2 Functional validation of HIF2A reporter systems 
 To validate whether the mCherry gene is functioning alongside the endogenous 
EPAS1 gene, evaluation was done for mCherry expression in relation to HIF2A mRNA 
and protein expression. By using lentivirally delivered CRISPR interference 
(CRISPRi), inhibition of HIF2A endogenous mRNA expression through sgRNA-
mediated recruitment of a repressive dCas9-KRAB protein was carried out187 (Figure 
18a). The catalytically inactive dCas9 does not generate double stranded break on the 
EPAS1 gene. H2AmC1-3 clones were transduced with a dCas9-BFP plasmid followed 
by a plasmid bearing HIF2A sgRNA constructs targeting the EPAS1 transcription start 
site (iHIF2A-1, iHIF2A-2, iHIF2A -3) (Figure 18a). Two of these sgRNA constructs, 
iHIF2A-1 and iHIF2A-3, are in a tandem format where two sgRNA targeting sequence 
were placed in tandem to one another that targets two different sites within EPAS1 
Figure 19.  (a) FACS analysis of mCherry fluorescence in H2AmC2 dCas9 cells 
transduced with different HIF2A-targeting sgRNA constructs. (b) FACS analysis of 
mCherry fluorescence in H2AmC3 dCas9 cells transduced with different HIF2A tandem 
sgRNAs compared to controls. Untransduced H2AmC2 and H2AmC3 as well as UOK101 
cells serve as a positive and negative control, respectively. 
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promoter region. This produces a synergistic control of a single gene for enhance 
repression187. iHIF2A-2 on the other hand only carries a single sgRNA targeting 
sequence. Analysis of relative mRNA levels of HIF2A in H2AmC2 and H2AmC3 
transduced cells showed that iHIF2A-1 and iHIF2A-2 caused a significant reduction 
when compared to the non-targeting sgRNA control (Scramble) (Figure 18b). These 
effects translated to the protein levels showed by Western blotting analysis (Figure 
18c). In contrast, iHIF2A-3 showed no reduction in both HIF2A mRNA and protein level 
suggesting its inefficiency in inhibiting HIF2A mRNA and protein expression (Figure 
18b and c). Moreover, a strong HIF2A protein band of the expected size was 
Figure 20. CRISPRi-based HIF2A inhibition in H2AmC1 cells. (a) Relative HIF2A mRNA 
levels in H2AmC1 dCas9 cells transduced with HIF2A-targeting sgRNAs or a non-
targeting control. Analysis was based on three technical repeats of single biological 
repeat. (b) Western blot analysis of H2AmC1 dCas9 cells transduced with HIF2A-
targeting sgRNAs or a non-targeting control. B-actin acts as a loading control. Analysis 
based on single biological repeat. (c) FACS analysis of mCherry fluorescence in 
H2AmC2 cells transduced with different HIF2A-targeting sgRNA constructs.  
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expressed by the reporter lines, and the HIF2A antibody did not detect any larger 
bands of ~150kDa, which is the expected size of a HIF2A-mCherry fusion protein 
(Figure 18c). This indicates that the T2A peptide was efficient in these systems.  
 Flow cytometry analysis of the transduced H2AmC clones was carried out to 
investigate whether the effects seen on the mRNA and protein levels of HIF2A affected 
the mCherry fluorescence. FACS analysis in H2AmC2 clones transduced with either 
iHIF2A-1 or iHIF2A-2 showed a marked decrease in mCherry fluorescence, closely 
mimicking the parental UOK101 cells (Figure 19a). iHIF2A-3 transduced H2AmC2 
cells showed no reduction in mCherry fluorescence, similar to that of the untransduced 
cells (Figure 19a). This change in fluorescence corroborates the finding on changes 
Figure 21.  (a) Western blot analysis of VHL-reintroduced H2AmC2 and H2AmC3 cells 
compared to the empty vector (EV) control. B-actin acts as a loading control. Analysis 
based on two biological repeats (b) Relative mRNA levels of VHL, CXCR4 and HIF2A in 
the H2AmC2 cells transduced with an empty vector (EV) or exogenous VHL (HA-VHL). 
(c) Relative mRNA levels of VHL, CXCR4 and HIF2A in the H2AmC3 cells transduced 
with an empty vector (EV) or exogenous VHL (HA-VHL). qRT-PCR analyses were based 
on triplicates of technical repeats with single biological repeats. 
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in mRNA and protein levels of these cells. These results were also replicated in the 
H2AmC3 cells (Figure 19b). HIF2A targeted H2AmC1 cells however showed very 
modest changes in the mCherry fluorescence when compared to H2AmC2 and 
H2AmC3 targeted cells (Figure 20). This suggests the possibility that within this clone 
mCherry is expressed at least partially independent of HIF2A. Hence, this clone was 
omitted from further analysis.  
 With HIF2A acting as the main effector in the VHL-HIF pathway, we 
investigated the interdependence of HIF2A mRNA, protein and mCherry fluorescence 
in H2AmC2 and H2AmC3 cells by transducing wildtype VHL. This resulted in a robust 
reduction in HIF2A protein expression (Figure 21a) and its subsequent downstream 
target gene expression, CXCR4114, with increased expression of VHL (Figure 21b and 
c). No significant reduction was seen in HIF2A mRNA expression. FACS analysis on 
the mCherry fluorescence of VHL-reintroduced H2AmC clones also showed no 
change closely mimicking the empty vector control cells (Figure 22). This suggests the 
absence of an auto-regulatory loop in the maintenance of high mRNA expression 
levels of HIF2A in these cells. 
Figure 22.   FACS analysis of mCherry fluorescence in H2AmC2 and H2AmC3 cells 
transduced with HA-VHL and empty vector. 
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3.4 Conclusion 
 To summarise this chapter, HDR-based knock-in method of an mCherry 
fluorescent gene following CRISPR-Cas9 double stranded break in the EPAS1 gene 
was successfully performed in the UOK101 ccRCC cells. The H2AmC clones derived 
from this knock-in experiment were shown to consist of the correct mCherry 
fluorescent gene within the right integration site of the EPAS1 gene. The mCherry 
gene integrated in these clones were also proven to be functional as it emits an 
mCherry fluorescence. As the mCherry fluorescent gene is integrated in the coding 
sequence of EPAS1, two H2AmC clones have been shown to express mCherry at 
levels that are in concordance with the changes seen in HIF2A mRNA and protein 
expression levels with great correlation.  Therefore, two validated HIF2A reporter 
systems were produced, the H2AmC2 and H2AmC3 systems. As an initial test on 
possible regulatory mechanism of HIF2A mRNA expression, these systems revealed 
that the high HIF2A mRNA expression level is not governed by HIF2A proteins in an 
auto-regulatory loop manner, prompting the need to interrogate other potential 
regulators.  
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Chapter 4: High-Throughput Screening Using HIF2A Reporter 
Systems 
4.1 Introduction 
The fluorescent properties of the HIF2A-mCherry reporter systems can be 
harnessed to interrogate potential regulators of EPAS1 gene expression through 
sgRNA enrichment in a pooled screening context. With the availability of 
oligonucleotide library synthesis technology, screening reagents for pooled formats 
are easier to produce with in silico-designed libraries synthesized as a highly complex 
pool of oligonucleotides233. These oligonucleotides are cloned as a pool to create a 
plasmid library which will then be used for virus production and screening. In contrast 
to arrayed screens, pooled screens are less labour intensive and therefore less 
expensive155. Moreover, the pooled screening method is feasible for long culture 
times, allowing more flexibility in the genetic interrogation procedure155. Importantly, 
with a pooled format, a variety of factors can be investigated simultaneously in a single 
cell system. 
The loss-of-function screen utilises designed sgRNA libraries targeting a set of 
potential genes involved in regulating HIF2A mRNA expression. This could be a set of 
transcription factors or chromatin regulators, for example. To isolate individual 
regulatory factors from the screen, a low multiplicity of infection (MOI) of the sgRNA 
library is implemented to obtain a high percentage of cells transduced with a single 
sgRNA construct155,234. Referring to Figure 19, when multiple integrations of sgRNA 
constructs per cell were carried out to inhibit mRNA and protein expression of HIF2A, 
a significant shift in mCherry fluorescence was observed. In theory, low MOI of sgRNA 
library would still be able to result in a shift of the mCherry fluorescence at the tail end 
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of the distribution depending on the efficiency of the sgRNA. There is also the 
possibility of a non-shift in the mCherry fluorescence attributed to sgRNA constructs 
within the pool of transduced cells having no effect on HIF2A mRNA and protein 
expression, thus normalizing the overall effect on mCherry fluorescence. 
Nevertheless, an sgRNA enrichment approach within specific mCherry population of 
cells would resolve these uncertainties with low MOI transductions. With evidence 
from Figure 18 and 19 that mCherry fluorescence closely mirrors the mRNA and 
protein expression levels of HIF2A, the lowest mCherry cell population would reflect 
cells transduced with sgRNA constructs targeting factors that positively regulates 
HIF2A mRNA expression. To test this for high-throughput screening, two independent 
experiments were carried out on H2AmC2 and H2AmC3 cells applying CRISPRi and 
CRISPR-Cas9 approach, respectively.  
 
4.2 Screening feasibility tests for the HIF2A-mCherry systems 
4.2.1 CRISPRi interrogation of H2AmC systems 
Figure 23. CRISPRi-based sgRNA enrichment strategy. (a) EGFP fluorescence in sgRNA-
transduced H2AmC_dCas9 cells. (b) mCherry fluorescence of a H2AmC_dCas9 
population that contains 10% of EGFP+ sgRNA-expressing cells. The bottom 10% of 
mCherry population was selected for further analysis of EGFP fluorescence.  
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 Using similar reagents from CRISPRi-targeted H2AmC2 and H2AmC3 
experiments shown in Figure 18, expression of EGFP fluorescent marker within the 
sgRNA vectors allows for the evaluation of the relationship between the presence of 
HIF2A-targeting constructs and mCherry fluorescence at the single cell level in a 
mixed population.  In this experiment, a low MOI of sgRNA constructs were introduced 
in the H2AmC_dCas9 cells, producing cells with ~10% EGFP positive fluorescence 
(Figure 23a). This leads to an estimated MOI of 0.11 with ~95% of the EGFP positive 
cells being infected by a single virus. In theory, infection with non-targeting sgRNAs 
would result in a uniform EGFP positive distribution in the mCherry cell population. In 
contrast, sgRNAs targeting HIF2A mRNA and protein expression would skew this 
EGFP distribution in relation to its effect on mCherry fluorescence. The percentage of 
EGFP positive cells within the lowest 10% of mCherry fluorescence population were 
evaluated to potentially isolate cells integrating sgRNAs targeting the best regulators 
Figure 24.  sgRNA enrichment in CRISPRi-transduced H2AmC systems. EGFP 
fluorescence in (a) H2AmC2_dCas9 and (b) H2AmC3_dCas9 cells with the lowest 10% 
mCherry fluorescence from analysis similar to Figure 23b. EGFP+, positive EGFP 
fluorescence. EGFP-, negative EGFP fluorescence.  
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of HIF2A mRNA expression (Figure 23b). Both non-targeting sgRNA and iHIF2A-3 
transduced H2AmC2_dCas9 cells showed no enrichment of EGFP positive cells within 
mCherry low population (Figure 24a). However, iHIF2A-1 and iHIF2A-2 transduced 
H2AmC2_dCas9 cells showed a marked increase in their EGFP positive cells within 
the low mCherry population (Figure 24a). These results were recapitulated in the 
H2AmC3_dCas9 transduced cells (Figure 24b) with both systems showing distinct 
enrichment of EGFP based on the effects of each sgRNA on the level of changes in 
HIF2A mRNA and protein expression seen in Figure 18. It is reliable to expect an 
enrichment of sgRNAs targeting factors that regulates mRNA expression of HIF2A in 
the H2AmC systems within the lowest mCherry population.  
Next, the effects of different mCherry population cut-offs on the level of 
enrichment for sgRNA-transduced EGFP positive cells were assessed. With 
decreasing levels of mCherry fluorescence, an increase in fraction of EGFP positive 
Figure 25.  Effects of different mCherry population cut-offs. Relative abundance of EGFP 
positive (EGFP+) and negative (EGFP-) H2AmC2_dcas9 (a) and H2AmC3_dCas9 (b) cells 
in populations with different levels of mCherry fluorescence.  
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cells were selected for in both iHIF2A-1 and iHIF2A-2 transduced H2AmC2_dCas9 
(Figure 25a) and H2AmC3_dCas9 (Figure 25b) cells. H2AmC_dCas9 cells transduced 
with the non-targeting sgRNA and iHIF2A-3 showed no changes (Figure 25). This 
correlates well with the effects seen on HIF2A mRNA and protein expression by the 
HIF2A-targeting constructs (Figure 18). Due to practical reasons that involved the cell 
sorting facility limit, the initial bottom 10% population cut-off was chosen for analysis. 
This cut-off also considered the balance between an adequate number of cells and 
high EGFP enrichment. When different population cut-off was inspected, even the 
lowest 1% of mCherry expressing cells had a significant amount of EGFP negative 
cells (Figure 25). Moreover, the lower the cut-off the less the number of cells that would 
be isolated, which would be unfavourable for the library screen. Thus, these 
optimization experiments suggest that the lowest 10% mCherry population cut-off is 
the most reasonable approach for the screen.  
 
4.2.2 CRISPR-Cas9 double-stranded break interrogation of the mCherry system 
Figure 26.  Generation of Cas9-expressing H2AmC subclones. (a) Western blot analysis 
of H2AmC2 and H2AmC3 cells transduced with lenti-Cas9-EGFP compared to 
untransduced control cells. B-actin acts as a loading control. Analysis based on single 
biological repeat (b) EGFP fluorescence of the single cell derived subclones of the 
respective H2AmC2 and H2AmC3 lenti-Cas9-EGFP cells. 
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 A Cas9 double-stranded break approach was employed in the screen, therefore 
sgRNA enrichment analysis had to be tested in such systems. To replicate the findings 
observed from the CRISPRi targeted cells (Figure 23 and 24), the H2AmC cells were 
transduced with a lentiviral plasmid carrying Cas9-EGFP.  These transduced cells 
were then sorted for EGFP positive cells into pools and single cell clones to achieve 
uniform Cas9 expression. The pooled cells were used to test for the presence of the 
FLAG-tagged Cas9 protein as shown in Figure 26a. When compared to the negative 
control, both Cas9-transduced H2AmC2 and H2AmC3 cells showed expression of 
FLAG-Cas9 protein (Figure 26a). The strongest EGFP-expressing subclones were 
isolated from each system (Figure 26b).  
 CRISPR-Cas9-based mutations of EPAS1 gene were carried out and the 
effects on mCherry fluorescence were observed in the sgRNA positive cells (Figure 
27). Plasmids of sgRNA constructs targeting HIF2A that expresses a BFP fluorescent 
gene was used (CTRL, sgEPAS1-1, sgEPAS1-5). Transducing these at low MOI into 
the Cas9-expressing H2AmC cells yields around 10% BFP positive fluorescence. A 
shift in the mCherry fluorescence was observed when the BFP positive cells of both 
Figure 27.  Cas9-based evaluation of sgRNA enrichment. mCherry fluorescence in (a) 
H2AmC2-Cas9 and (b) H2AmC3-Cas9 cells transduced with non-targeting control 
sgRNA (CTRL), sgEPAS1-1 or sgEPAS1-5. Also included is the normalized cell counts 
for each construct in the combined population with the lowest 10% of mCherry 
fluorescence. 
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sgEPAS1-1 and sgEPAS1-5 transduced H2AmC_Cas9 cells were compared to the 
non-targeting control (CTRL) (Figure 27). A greater difference in mCherry 
fluorescence can be seen in the H2AmC3_Cas9 cells (Figure 27b). Regardless, a 
combined analysis of the control and HIF2A-targeted cells revealed that in the 
population of lowest 10% of mCherry fluorescence, enrichment of HIF2A-targeted cells 
can be observed in both H2AmC2_Cas9 and H2AmC3_Cas9 cells. In H2AmC3_Cas9 
cells, 5.5 times the amount of sgEPAS1-5 and 3.1 times the amount of sgEPAS1-1 
transduced cells are recovered in the overall bottom 10% population when compared 
to the CTRL transduced cells (Figure 27b). The overall bottom 10% population of 
H2AmC2_Cas9 cells recovered 1.7 times and 2.1 times the amount of sgEPAS1-5 
and sgEPAS1-1 transduced cells compared to CTRL, respectively (Figure 27a). 
Hence, the isolation of a bottom 10% mCherry population cut-off for the screen may 
reliably enrich for the sgRNAs targeting factors that support mRNA expression of 
HIF2A. Only the Cas9-subclones of H2AmC2 and H2AmC3 cells were used for 
screening experiments from here onwards.  
 
4.3 Screening of HIF2A mCherry systems 
4.3.1 Transcription Factor Library Screen 
 The aberrant mRNA expression level of HIF2A in ccRCC can be explained by 
potential deregulation in its transcriptional control as commonly seen in cancer 235. 
Transcription factors (TFs) have the potential to produce profound changes in gene 
expression programs. It is known that some master TFs, also called as lineage 
regulators, are sufficient to establish control of the gene expression programs that 
define cell identity235. This may apply to the highly specific high HIF2A mRNA 
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expression level seen in ccRCC. Furthermore, the interrogation of the transcription 
factor network involved in the regulation of HIF2A mRNA expression would delineate 
the regulatory mechanism behind ccRCC progression, possibly providing other 
avenues for therapeutic targeting.   
To investigate the transcription factors involved in the high HIF2A mRNA 
expression observed in ccRCC, a focused library was generated of 9102 sgRNAs 
targeting a total of 1286 transcription factor genes by Saroor Patel, a postdoctoral 
researcher in the lab. A list of genes encoding transcription factors were compiled 
from213. This library consists on average seven sgRNAs per gene with sequences 
obtained from Wang et al.214. One hundred non-targeting negative controls were also 
included in the library. The library was cloned by Saroor Patel using a Gibson 
assembly method215 with amplified custom oligos. 
 
4.3.1.1 Screening procedure 
 A major practical aspect of a pooled screen is maintaining adequate 
representation of the library at all steps for accurate quantification. Based on a 
Figure 28.  Schematic showing the screening process with the transcription factor library. 
A pool of sgRNAs targeting transcription factors was cloned into a lentiviral vector. H2AmC2 
and H2AmC3 clones expressing Cas9 were transduced with the virus, followed by isolation 
of the cells with the lowest 10% of mCherry fluorescence. Second isolation of the lowest 
10% of mCherry fluorescence of the sorted cells was done to isolate the lowest 1%. sgRNA 
enrichment assessed by high-throughput screening.  
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simulation of cell culture, the representation can affect the distribution of the library 
owing to random chance. For example, in such a simulation at low representation 
(50x), more perturbations will fall outside 2 standard deviations of the initial normal 
distribution leading to erroneous interpretation of dropout or enrichment. This source 
of noise can be mitigated by achieving a representation of 500x or greater234. Aiming 
to balance a reasonably high efficiency of infection to reduce amount of cells discarded 
because they were not infected, while minimizing the number of cells receiving more 
than one perturbation to minimise noise, around 10% infection efficiency of the library 
was applied. This means that around 12 million cells have to be transduced to reach 
a 1000X representation of sgRNAs. This representation is chosen as the sequencing 
of the plasmid library showed around 1000x difference between the lowest and highest 
Figure 29. Validation of TF screening samples. (a) PCR amplification of the guide 
sequence (274bp) from each sample along with their respective water control (WC). (b) 
Sequencing of the pooled sample showing multiple peaks signifying multiple sgRNA 
sequences. 
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represented sgRNAs. Furthermore, it has been shown to be a faithful method to 
ensure adequate representation of the library with minimal noise for the screen234,236. 
A total of 120 million cells were seeded for transduction and then transduced with the 
transcription factor (TF) library with a multiplicity of infection of 0.11 that equates to 
10% BFP positive cells. This means that around 12 million cells were transduced with 
the TF library.  
An important note on the TF library plasmid is that it carries a Hygromycin 
resistant gene and so does the reporter construct that was integrated in the H2AmC 
systems. This poses some difficulty in the isolation of positively transduced cells in the 
H2AmC systems. In spite of this, TF library screening was carried out as positively 
transduced cells could be isolated using FACS by gating for the highest EGFP positive 
fluorescence instead. Thus, only these positively transduced cells were isolated and 
considered for subsequent sorting steps. The first sort occurred 2 weeks after infection 
and it isolated the bottom 10% of the mCherry population. Around three million cells 
were sorted from the bottom 10% mCherry population which were then reseeded to 
recover and grow. Prior to further sorting, these sorted cells were also collected as the 
bottom 10% samples. A second sorting phase was carried out with the knowledge that 
sgRNAs targeting regulators that most affect the mRNA expression of HIF2A would 
be enriched at the very bottom population (Figure 28). The bottom 10% of the sorted 
population was isolated to obtain the bottom 1% of the original mCherry population. 
Around 5 million cells were isolated from this step for the H2AmC2 system but less 
were recovered from the H2AmC3 system due to technical problems as these cells 
did not grow well following their reseeding after the first sorting step. All the recovered 
cells from the second sort were reseeded again and left to grow before collecting 
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samples along with the unsorted control cells which were maintained throughout the 
screen for further analysis. The bottom 1% samples along with the bottom 10% 
samples would highlight the stepwise enrichment of sgRNAs targeting important 
regulators when compared with the unsorted control samples. Samples were PCR 
amplified, purified and prepared for deep sequencing (Figure 28). Purified samples 
were checked for PCR amplified bands of the guide sequence that is 274bp and 
sequencing of pooled samples came back positive with multiple peaks that represents 
multiple sgRNAs from the library (Figure 29).  
 
4.3.1.2 Analysis of screening 
Sequencing data was aligned by Sakari Vanharanta, the principal investigator 
of the lab, with BowTie sequence alignment software to produce normalised counts of 
each sgRNA per million reads for each H2AmC systems. The normalised sgRNA 
Figure 30. Analysis of the sgRNA counts per million reads in TF screen. (a) Correlation 
plot of the normalized sgRNA counts in unsorted H2AmC2 and H2AmC3 cells. PCC, 
Pearson’s Correlation Coefficient. (b) Breakdown of total sgRNAs and control sgRNAs 
analysed in the screen after the removal of sgRNAs with less than 5 normalized counts in 
the unsorted population.  
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counts for the unsorted control samples were then plotted between the two systems 
to produce a correlation plot with a correlation coefficient of 0.6453, showing moderate 
correlation (Figure 30a). Analysis of these normalised sgRNA counts showed that 490 
out of 9102 sgRNAs had less than 5 counts per million reads in the H2AmC2 unsorted 
sample, while only 170 sgRNAs in the H2AmC3 unsorted sample had less than 5 
counts per million reads (Figure 30b). Less than 5.5% of the total sgRNAs had <5 
counts per million reads and when these sgRNAs were removed from further analysis, 
only one gene was excluded (Figure 31a). Moreover, only 2 out of 100 non-targeting 
control sgRNAs were excluded from analysis (Figure 30b). Assessment of the amount 
of sgRNAs analysed per gene showed that the majority of genes retained all 7 sgRNAs 
in both H2AmC systems after exclusion of sgRNAs with <5 counts per million reads 
(Figure 31b).  
 The counts per million reads of the bottom 10% sorted samples were compared 
to those of the unsorted controls to yield the first fold change enrichment scores in 
each H2AmC system. The second fold change enrichment scores were determined 
between the bottom 1% sorted samples and the bottom 10% sorted samples. It is 
important to note that the second fold change enrichment scores in the H2AmC3 
Figure 31.  Gene level analysis of TF screen. (a) Total genes and (b) number of sgRNAs 
per gene analysed after the removal of sgRNAs with less than 5 normalized counts in the 
unsorted population.  
- 90 - 
 
system came out inconclusive in the screening analysis as HIF2A sgRNAs wasn’t 
enriched. This could be attributed to technical difficulties in obtaining the second 
H2AmC3 sorted sample as mentioned earlier. This means that further analysis 
involving the second sorting phase only includes the sample from the H2AmC2 
system. Focusing on the first fold change enrichment for EPAS1 sgRNAs alone 
between the two systems produced a great correlation coefficient of 0.7291 (Figure 
32a). Furthermore, only 4 out of 7 sgRNAs from this positive control gene showed high 
enrichment in both systems. Additionally, these four EPAS1 sgRNAs showed further 
Figure 32.  HIF2A as the positive control in the TF screen analysis. (a) Fold enrichment 
of HIF2A sgRNAs in H2AmC2 and H2AmC3 cells. (b) Z-scores of the average median 
enrichment for the top 4 scoring sgRNAs of each gene in the H2AmC2 and H2AmC3 
cells, plotted between the bottom 10% and bottom 1% sorted samples.  
HIF2A 
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enrichment within the second fold change enrichment scores of the H2AmC2 system. 
Hence, potential regulators of HIF2A mRNA expression would reliably show similar 
trends. For this reason, analysis of other genes for their respective fold change 
enrichment scores would only consider the top 4 enriched sgRNAs. To investigate this, 
a gene level analysis was carried out by measuring the median top 4 sgRNA 
enrichment scores for the bottom 10% enrichment for each gene in both H2AmC 
systems, while a median top 4 sgRNA enrichment scores were only calculated for the 
bottom 1% enrichment of H2AmC2 system. Average scores between the two systems 
were calculated for the bottom 10% enrichment and this were then plotted against the 
median top 4 gene enrichment within the bottom 1% of H2AmC2 system (Figure 32b). 
As expected HIF2A was the most enriched gene and possible regulators, as 
highlighted in Figure 32b, could be identified from the genes closest to HIF2A that 
showed enrichment in both sorted populations. Median enrichment of all non-targeting 
control sgRNAs was sequestered within the centre of the plot.   
 To determine the validity of the potential hits from the gene level analysis, their 
statistical significance was tested through a permutation-based analysis (Figure 33). 
Re-sampling techniques that are employed in the permutation tests correct for the 
Figure 33.  Significance analysis of the TF screen. (a) Permutation (1000x) of gene 
enrichment scores. Observed data in red, simulated data in blue. (b) Distribution of FDR-
corrected p-values for each gene. 
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occurrence of false positives237. This differs from the traditional multiple-testing 
corrections, such as Bonferroni and Benjamini and Hochberg (B&H) corrections, 
whereby permutation-based tests estimate statistical significance directly from the 
data being analysed238 instead of using individual association scores based on family-
wise corrections237. Furthermore, irregularities of the observed data are maintained in 
the permutated data sets and are thus included in the estimation of the permutation 
probability239. The data that was initially analysed from the TF screen is known as the 
observed data. To obtain the permutated data, the original sgRNA counts/million reads 
were sampled 1000 times and the same analysis was applied to this sampled data as 
per the observed data. In comparison to the permutated data, the observed data 
clearly highlights HIF2A as the most significant scoring hit with a false discovery rate 
(FDR)-corrected P-value of <0.001 (nominal P-value <7.806e-07) (Figure 33a). This 
means no single permutated data scored higher than HIF2A observed score. Looking 
at the next best scoring hit, LHX3, its FDR adjusted P-value came out insignificant 
(Figure 33b). Furthermore, manual analysis of the top 147 scoring sgRNAs showed 
no duplicates of the highlighted genes in Figure 32b, while sgRNAs targeting HIF2A 
came up three times and the non-targeting controls came up twice.  
This pioneering screen in the H2AmC systems validates its use for high-
throughput genetic studies as the positive control, HIF2A, came out as the best scoring 
significant hit. However, it is difficult to be completely sure that the outcome of not 
isolating other significant factors could be attributed to the efficiency of the systems. 
More screens in the H2AmC systems utilising different interrogation library have to be 
tested to draw conclusions.  
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4.3.2 Chromatin Factor Library Screen 
Apart from the deregulation of transcription factors in cancer transcriptional 
program, other factors involved in transcriptional control such as chromatin factors 
have been shown to play a key role. Chromatin factors commonly functions to facilitate 
the maintenance of positive or negative gene expression states by efficiently 
conveying transcriptional signalling from enhancers to promoters of genes. They 
function globally and therefore their deregulation can have profound effects on the 
gene expression program of cells240. Moreover, chromatin factors as supporters of 
cancer-specific transcriptional programmes are emerging as potential therapeutic 
target molecules. An example involves the direct bromodomain inhibition in 
carcinomas harbouring fusions of BET bromodomain coactivators such as BRD4161. 
Bromodomains specifically bind acetylated lysine residues in histones to serve as 
chromatin-targeting modules that decipher the histone acetylation code241. Tumours 
of the lung and head and neck cancer that express chimeric, oncogenic cofactors 
BRD4-NUT are effectively inhibited by the chemical probe JQ1242. Moreover, BRD4 
inhibition was also established as a therapeutic strategy to inhibit MYC-dependent 
transcriptional signalling in multiple myeloma, diffuse large B cell lymphoma, and 
Figure 34.  Schematic showing the screening process with the chromatin library. A pool 
of sgRNAs targeting chromatin factors was cloned into a lentiviral vector. H2AmC2 and 
H2AmC3 clones expressing Cas9 were transduced with the virus, followed by isolation of 
the cells with the lowest 10% of mCherry fluorescence. sgRNA enrichment assessed by 
high-throughput screening. 
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mixed lineage leukaemia (MLL)243. Hence, looking into potential deregulation of 
chromatin factors in ccRCC that may have a positive effect on HIF2A mRNA 
expression could help us better understand its regulatory mechanism.  
In order to interrogate the chromatin factor dependencies of HIF2A mRNA 
expression in ccRCC, a focused library was generated of 7617 sgRNAs targeting a 
total of 836 known and potential chromatin factors in collaboration with Saroor Patel. 
Genes encoding known or putative chromatin factors were identified from previously 
curated lists216–219. The library contained on average nine sgRNAs per gene with 
Figure 35.  Validation of chromatin library screening samples. (a) PCR amplification of the 
guide sequence (274bp) from each sample along with their respective water control (WC). 
(b) Sequencing of the pooled sample showing multiple peaks signifying multiple sgRNA 
sequences. 
- 95 - 
 
sequences obtained from Wang et al.214. A total of 100 non-targeting negative controls 
were included in the library along with a set of sgRNAs targeting 10 known essential 
genes214. The library was cloned by Gibson assembly215 of amplified custom oligos.  
 
4.3.2.1 Screening steps and procedure 
By adjusting the number of transduced cells, the sgRNA representation of the 
library can be controlled. With a total of 7617 sgRNAs and sequencing of the plasmid 
library showing a 1000x difference between the smallest and largest represented 
sgRNA, around 8 million cells have to be transduced. As mentioned in the transcription 
factor (TF) screen, a 1000x sgRNA representation is a faithful method to ensure 
adequate representation of the library with minimal noise for the screen234,236, 
H2AmC2 and H2AmC3 Cas9 cells were seeded at 5 million cells per plate for a total 
of twelve 15cm plates. After a 24-hour doubling time, a total of around 120 million cells 
Figure 36. Analysis of the sgRNA counts per million reads in chromatin library screen. (a) 
Correlation plot of the normalized sgRNA counts in unsorted H2AmC2 and H2AmC3 cells. 
PCC, Pearson’s Correlation Coefficient. (b) Breakdown of total sgRNAs and control 
sgRNAs analysed in the screen after the removal of sgRNAs with less than 5 normalized 
counts in the unsorted population. 
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were transduced with the chromatin library at a low MOI. This results in ~12 million 
infected cells, hence ensuring >1000X representation of sgRNAs. As the doubling time 
for cells differ from one to the other and dependent on growth conditions, aiming for 
more cells than needed would eliminate any possible detriment to the representation 
of the sgRNAs in the screen in this early stage. Puromycin selection was carried out 
to select for cells with successful transduction only. FACS were then used to further 
isolate the population with the lowest mCherry expression. Isolated cells were then 
pelleted along with unsorted control cells that were propagated for the same amount 
of time as the sorted samples. These samples were purified and prepared for high-
throughput sequencing to assess the changes in the representation of sgRNAs in 
different samples (Figure 34). Purified samples were checked for PCR amplified bands 
of the guide sequence that is 274bp and sequencing of pooled samples showed 
multiple peaks signifying multiple sequenced sgRNAs from the library (Figure 35).  
 
 
Figure 37.  Gene level analysis of chromatin library screen. (a) Total genes and (b) 
number of sgRNAs per gene analysed after the removal of sgRNAs with less than 5 
normalized counts in the unsorted population. 
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4.3.2.2 Analysis of screen 
Sequencing results were extracted and aligned by Sakari Vanharanta using a 
BowTie sequence alignment software to obtain normalised counts/million reads for 
each sgRNA within each H2AmC system for analysis. The counts/million reads of each 
sgRNA construct of unsorted control was plotted for both H2AmC2 and H2AmC3 
system. This resulted in a good correlation between the experimental systems to yield 
a Pearson Correlation Coefficient (PCC) of 0.84 (Figure 36a). Further assessment of 
the counts/million reads for each sgRNA showed that 101 out of 7605 sgRNAs within 
the H2AmC2 system has less than 5 counts/million reads, while in H2AmC3 system 
only 77 sgRNAs had less than 5 counts/million reads (Figure 36b). All non-targeting 
control sgRNAs were retained in the analysis. Thus only <1.5% of sgRNAs had <5 
counts/million reads in the initial population and excluding such sgRNAs retained 
100% of the target genes (Figure 37a). Moreover, more than 88% of the genes 
retained all 9 of their sgRNAs, while only 2 genes analysed with 4 sgRNAs, the lowest 
number of sgRNAs retained (Figure 37b). The excluded sgRNAs were either lost 
during library preparation due to technical reasons, or they targeted genes that 
Figure 38.  Quality control of CRISPR-Cas9 screen. (a) Average median enrichment for 
all genes analysed in the screen between the pooled plasmid control and the H2AmC 
screening controls. (b) Top 10 most depleted genes in the H2AmC screening controls 
compared to the pooled plasmid control. Essential genes are highlighted in red.  
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affected cell viability. Indeed, a number of genes like SF3B3 and PCNA were included 
in the library as control genes.  
 A formal analysis comparing the unsorted control samples to the plasmid that 
was used for virus production was carried out to understand how different genes 
change in their counts as they go through the screen. The fold change enrichment of 
each sgRNA was determined when the counts for the unsorted control samples were 
compared to the plasmid counts. Average median sgRNA enrichment for each gene 
between the two experimental systems (Figure 38a) were calculated and this shows 
that known essential genes were highly represented among the most significantly 
depleted genes. The top ten most depleted genes isolated essential genes214 such as 
SF3B3, PCNA, FARSA, EIF4A3 and ATP6V1A (Figure 38b).  
Figure 39.  sgRNA analysis of HIF2A as the positive control. (a) Fold enrichment of 
HIF2A sgRNAs in H2AmC2 and H2AmC3 cells. (b) Average enrichment of all sgRNAs 
analysed in the screen with a snapshot of the top 10 scoring sgRNAs. 
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 Fold change enrichment of each sgRNA was also determined when comparing 
the H2AmC sorted samples to their respective unsorted controls. Looking specifically 
at HIF2A as a positive control, it was found that 8/9 sgRNAs showed evidence of 
enrichment in the mCherry low population with a good correlation coefficient of 0.809 
between the two reporter systems (Figure 39a). One HIF2A sgRNA was excluded due 
to low representation. A rank analysis of the enrichment for all sgRNAs clearly proved 
HIF2A sgRNAs to be the most enriched, with 6/10 top scoring sgRNAs targeting HIF2A 
(Figure 39b). Manual inspection of the top-50 scoring sgRNAs showed no other gene 
that contained more than one sgRNA whereas non-targeting control sgRNAs 
appeared twice.  
Gene level analysis was carried out by combining data from all sgRNAs for 
each gene in both systems. Normalised median enrichment scores (z-scores) were 
produced for each gene in each system and plotted to show that HIF2A was by far the 
most strongly enriched gene in the mCherry low population (Figure 40). No other gene 
Figure 40.  Z-scores of the median sgRNA enrichment for all genes in the H2AmC2 and 
H2AmC3 cells. CTRL, control.  
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portrayed anything similar to the scores seen for HIF2A. In fact, most genes scored 
close to what was observed in the non-targeting control. 
To test the statistical significance of the result, a permutation-based 
approach238 was implemented to calculate empirical P-values for the gene level 
enrichment scores. Observed data represents the results obtained thus far for each 
gene in both systems. Permutated data was obtained by sampling the original sgRNA 
counts/million reads for 1000 times and running the entire analysis again in exactly the 
same way as the observed data. Comparing the observed data to the expected 
permutated data clearly highlighted HIF2A as the most significant hit with an FDR 
adjusted P-value of <0.001 (nominal P-value <1.195e-06) (Figure 41a). This translates 
to no single permutated data scoring higher than that of the observed HIF2A data. As 
expected, the second-best scoring gene in the observed data produced a non-
significant P-value when compared to the permutated data (Figure 41b). Therefore, 
no other factor reached statistical significance.  
 
 
 
Figure 41.  Significance analysis of the chromatin library screen. (a) Permutation (1000x) 
of gene enrichment scores. Observed data in red, simulated data in blue. (b) Distribution 
of FDR-corrected p-values for each gene. 
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4.4 Conclusion 
 In summary, both H2AmC2 and H2AmC3 systems have been shown to be 
feasible for a high-throughput pooled-based genetic screening. Firstly, sgRNA 
enrichment experiments carried out on the H2AmC systems showed an enrichment of 
sgRNAs that targets HIF2A gene in the lowest 10% mCherry population. This means 
that both H2AmC systems are capable of faithfully isolating important sgRNAs that 
targets positive regulators of HIF2A mRNA expression. Furthermore, this experiment 
highlights the fact that screening methods utilising pools of sgRNAs can be 
implemented in the H2AmC systems. Two separate high-throughput screenings were 
carried out in both H2AmC systems, interrogating transcription factors (TF) and 
chromatin factors, respectively. In the TF library screen, out of a total of 9102 sgRNAs 
targeting 1286 TF genes, only the positive control, HIF2A, came out as the sole 
significant hit following permutation-based analysis. In the chromatin factor library 
screen, from a total of 7605 sgRNAs targeting 838 chromatin factor genes, HIF2A also 
came out as the only significant hit with no other factors coming up as significant. 
Despite the lack of novel regulators of HIF2A mRNA expression isolated from these 
screens, the results confirm the technical validity of our screening approach in the 
H2AmC systems. This means that these systems can be used further in more 
sophisticated libraries interrogating whole genome to small compounds.  
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Chapter 5: Development and High-Throughput Screening of 
CXCR4 Reporter Systems 
5.1 Introduction 
 The chemokine receptor gene, CXCR4, has been shown to be a direct 
downstream target of HIF2A114. It has also been proven to be overexpressed in renal 
cell carcinoma and plays a role in metastasis134,139. With the aim of delineating the 
regulatory mechanisms of HIF2A mRNA expression in ccRCC, unravelling its 
subsequent activity with novel co-factors within the gene expression program of 
CXCR4 could also be therapeutically informative. In fact, the regulatory factors that 
are important for the mRNA expression of HIF2A could also play a role in the mRNA 
expression of HIF2A target genes. Generating new systems with HIF2A target genes 
like CXCR4 and utilising it alongside the HIF2A reporter systems would allow for a 
more in-depth interrogation of the HIF2A regulatory landscape.  
 Following the development of the HIF2A reporter systems with the HDR 
method, a study was published on the knock-in of a reporter gene in vivo through 
NHEJ repair mechanism204. This method was termed homology-independent targeted 
integration (HITI) as it does not utilise donor plasmids with any homology arms and 
recruits a much smaller form of plasmid template called a minicircle204. The knock-in 
efficiency that was recorded in this study in HEK293 cells was around 50% with no 
indel mutations, which is much higher than any recorded HDR knock-in efficiencies. A 
comparison was also carried out with traditional HDR methods and efficiencies came 
out much lower than the HITI method204. With this new knowledge in mind and the 
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possibility of improving the development process of reporter systems following the 
H2AmC systems, the HITI method was adopted into the production line of CXCR4 
reporter systems.  
 The HITI knock-in method recruits a minicircle carrying a fluorescent gene and 
an sgRNA target sequence that is complementary to the target site on the gene of 
interest. The respective sgRNA would then introduce a double stranded break on both 
the minicircle as well as the endogenous gene. This initiates an NHEJ repair 
mechanism with the potential of inserting the fluorescent gene from the minicircle into 
Figure 42. Schematic of NHEJ-based targeted genome editing using HITI donor minicircle 
plasmid. The same sgRNA target sequence are cleaved in both the minicircle plasmid and 
the endogenous gene. Cleaved minicircle acts as a donor template for an NHEJ-based 
repair. This repair with the mCherry construct integration occurs one of two ways, forward or 
reverse direction. Forward direction is the preferred method of integration as sgRNA target 
sequence is not reformed for further Cas9 cleavage. Successful integration selected for 
based on mCherry fluorescence. Orange pentagon, Cas9/sgRNA target sequence. Black 
line within orange pentagon, Cas9 cleavage site. DSBs, double stranded breaks.  
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the site of integration. Since no homology arms are involved, integration of the 
construct could occur in one of two orientations. The orientation that is more expected 
is when the sgRNA target sequence is not reformed after integration (forward 
direction) as the sgRNA will continue to cut the sequence if integration occurs in the 
reverse direction (Figure 42). Cutting of reverse integrated sequence will continue until 
the forward integration occurs or until insertions or deletions (indels) are formed204. 
Successful forward integration is then validated through multiple experiments.  
 
Figure 43. Minicircle plasmid production for HITI-based mCherry integration in the 3’ UTR 
of CXCR4 gene. With the induction of arabinose, ΦC31 integrase is turned on along with 
the Sce-I endonuclease genes. ΦC31 integrase produces the minicircle plasmid as well as 
the bacterial backbone plasmid from the parental plasmid. The Sce-I endonuclease then 
degrades the bacterial backbone plasmid.  
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5.2 CRISPR-Cas9 genome engineering of CXCR4 
5.2.1 HITI Minicircle Template Design 
Minicircles are produced from parental plasmids carrying the desired transgene 
with the help of an engineered E. coli strain. The cloning of the transgene into the 
parental plasmid occurs within its multiple cloning site (MCS) with no promoters 
upstream of it (Figure 43). This ensures no expression of the transgene until it is 
rightfully integrated in the genome. The ZYCY10P3S2T E. coli bacterial strain consist 
of an arabinose-inducible system that expresses the ФC31 integrase and the Sce-I 
endonuclease simultaneously244. The ФC31 integrase generates the minicircle 
plasmid from the parental plasmid upon arabinose induction. The parental plasmid 
also consists of 32 copies of Sce-I restriction sites that are recognised by the Sce-I 
Figure 44. Minicircle diagnostic digest test for CXCR4 minicircle plasmids. Both minicircle 
sample and the parental sample were digested with a single restriction enzyme to form 
linear DNAs. Both CXCR4-sg1 and CXCR4-sg2 minicircles showed a much smaller band 
compared to their parental samples. No parental DNA was observed in the minicircle 
samples. Minicircles produced are pure and ready for transfection. sg, sgRNA. MC, 
minicircle. 
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endonuclease for digestion and this ultimately destroys the leftover parental backbone 
plasmid244. The minicircle plasmid on the other hand lacks Sce-I restriction sites, thus 
remains intact (Figure 43). This procedure ensures no contamination of the parental 
plasmid once the minicircle plasmid have been generated (Figure 43 and 44).  
The transgene for the integration in the CXCR4 locus is made up of the mCherry 
fluorescent gene. Since the minicircle plasmid template possess no homology arms, 
the target site for the integration of the mCherry fluorescent gene needs to be in the 
untranslated region (UTR) of the CXCR4 gene to prevent possible mutations in the 
coding sequence of the endogenous gene. In this case the 3’ UTR region was chosen 
instead of the 5’ UTR to be the site of integration to ensure that the fluorescent gene 
is expressed by the same endogenous CXCR4 promoter (Figure 43). As the site of 
integration is located after the STOP codon of the CXCR4 exon, an internal ribosome 
entry site (IRES) sequence was fused to the mCherry gene within the minicircle 
construct. The transcription of the mRNA sequence containing the CXCR4 gene-
IRES-mCherry construct by the endogenous promoter would then be translated into 
two independent proteins225. This ensures the reporter protein remains fully functional 
while preserving the endogenous mRNA expression of CXCR4 as much as possible. 
Furthermore, an sgRNA target sequence complementary to the integration site of the 
3’ UTR region of CXCR4 was included in the fusion fragment upstream of the IRES 
sequence. Two different sgRNA sequences (CXCR4-sg1, CXCR4-sg2) targeting the 
3’ UTR of CXCR4 were selected that lack known polymorphisms within the PAM 
sequence and the 20-nucleotide target sequence to ensure precise targeting. The 
complete fluorescent fusion construct was then cloned into the MCS of the parental 
plasmid to complete the template.  
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The parental plasmid with the cloned mCherry fluorescent construct was then 
converted into a minicircle plasmid. Firstly, the ZYCY10P3S2T competent bacteria 
was transformed with the parental plasmid carrying the mCherry construct. Following 
inoculation of a picked colony in kanamycin-containing culture overnight, a minicircle 
induction mix containing the arabinose solution was added into the culture and left to 
incubate. Bacteria mix was then pelleted and conventional plasmid DNA extraction 
methods were carried out to yield the purified minicircle. To determine the purity of the 
minicircles produced, these plasmids were digested with a restriction enzyme to form 
a linear plasmid. When compared to the digested parental plasmid, the minicircle 
plasmid formed a much smaller sized band owing to its smaller size (Figure 44). 
Importantly, no contamination of the parental plasmid DNA can be seen in the digested 
minicircle plasmid sample (Figure 44). Thus, the quality of the minicircles produced in 
the induction step is pure and can be used for transfection. 
 
 
Cell Line Transfection Condition Cell Viability Positive 
cells (%) 
A498 4ul Lipo (1ug DNA: 1ul Lipo) Confluent, little death 1.9% 
 
10ul Lipo (1ug DNA: 2.5ul Lipo) Confluent, little death 7.7% 
 
20ul Lipo (1ug DNA: 5ul Lipo) ~90% confluent, some death 5.6% 
Cell Line Program Cell Viability Positive cells (%) 
786-M1A T-20 ~40% confluent in 6WP 52.1% 
X-05 ~50% confluent in 6WP 34.7% 
Figure 45. Optimization of transfection conditions in ccRCC cell lines. Lipofectamine 2000 
transfection methods were used for A498 cells, in particular the 10uL Lipofectamine 
condition. Nucleofection methods were used for 786-M1A cells. Percentage of positive cells 
based on percentage of BFP positive fluorescent cells after transfection. Cell viability was 
estimated under the microscope. 
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5.2.2 HITI knock-in of mCherry fluorescent reporter 
As a step to streamline the production of reporter systems, cell lines with Cas9 
stably integrated into the genome is used to generate reporter clones. This eliminates 
the need to transfect an additional Cas9-expressing plasmid for the generation of 
reporter clones. Furthermore, successful Cas9-expressing clones can be used straight 
away for pool based genetic screens following experimental validations. Based on 
RNA-seq analysis in the lab carried out by Sakari Vanharanta, ccRCC cell lines with 
high mRNA expression of CXCR4 was picked to constitutively express Cas9. This 
includes 786-M1A (metastatic derivative of 786-0), along with A498 and RFX631 cells. 
A lenti-Cas9-blast (LCB) plasmid was used to transduce these cells followed by a 
blasticidin selection process to select for a pool of positive Cas9 cells that will then be 
used as parental cells for reporter generation. 
Optimizations were carried out to determine the best transfection conditions for 
each cell line. Nucleofection method that uses an electroporation-based transfection 
was found to be the most optimal method for the 786-M1A-LCB cells. The nucleofector 
program chosen was the T-20, which has a much higher transfection efficiency 
compared to the X-05 program and with reasonable cell viability (Figure 45). For the 
A498-LCB and RFX631-LCB cells, a Lipofectamine-based transfection was used 
instead with a 10 µL Lipofectamine condition (Figure 45). These transfections were 
carried out with the two respective CXCR4 minicircles (CXCR4-sg1-MC, CXCR4-sg2-
MC) individually along with the px330 plasmids carrying the respective sgRNAs. A 
control of BFP expressing plasmid was also included to confirm positive transfection. 
Nucleofection was performed on trypsinized 786-M1A-LCB cells at a total of 1 million 
cells for each condition. Nucleofected cells were then plated into 6 well plates with 
fresh media to recover and grow. A498-LCB and RFX631-LCB cells were transfected 
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at around 95% confluency with Lipofectamine 2000 transfection reagent. The ratio of 
total amount of plasmid DNA to Lipofectamine is 1µg:2.5µL. 
 Following confirmation of BFP positive cells signifying successful transfection, 
these cells were sorted for mCherry positive fluorescence into single cell clones. This 
allows isolation of a homogenous population of cells carrying the same integration with 
uniform mCherry fluorescence. Out of the 3 cell lines only 786-M1A-LCB and A498-
LCB transfected with CXCR4-sg2-MC plasmid template showed positive mCherry 
fluorescence. Only less than 1% showed mCherry fluorescence out of the total 
transfected cells (Figure 46). These positively-gated cells were sorted into 96-well 
Figure 46. Single cell sorting of transfected (a) A498_LCB and (b) 786-M1A_LCB cells 
for mCherry fluorescence. Gating of positive mCherry cells were determined based on 
their respective parental controls. 
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plates consisting of conditioned media for 2 weeks to grow. The resulting clones were 
then left to expand further a visible mCherry fluorescence under the microscope, 
hence isolating the best clones more effectively. 
 
5.3 Analysis of CXCR4 mCherry single cell clone system 
5.3.1 Validation of mCherry integration in CXCR4 locus 
 Isolated clones from transfected 786-M1A-LCB and A498-LCB cells were 
further analysed using FACS to quantitatively identify the best clones based on the 
level of mCherry fluorescence. Two clones were chosen from each cell line, hereafter 
referred to as M1A-CXCR4-mCherry-single-cell-clone 1-2 and A498-CXCR4-
mCherry-single-cell-clone 1-2 or M1CXmC1-2 and A4CXmC1-2 (Figure 47 and 48). 
Figure 47. Validation of A4CXmC clones. (a) FACS analysis of mCherry fluorescence in 
two A4CXmC clones grown as a monolayer (blue) compared to the parental A498_LCB 
control cells (red). Orange peak signifies the mCherry fluorescence of the two A4CXmC 
clones grown in spheroids. (b) Genomic amplification of the CXCR4-mCherry integration 
site in single-cell derived clones of A4CXmC. Arrow signifies successful integration. WC, 
water control. GC, genomic control.  
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FACS analysis of A4CXmC clones showed around 6 to 7-fold higher mCherry 
fluorescence than its parental control (Figure 47a), whereas M1CXmC clones showed 
around 3 times higher mCherry fluorescence than their parental control (Figure 48a). 
Using primers that span the site of integration in the CXCR4 3’ UTR, genomic 
amplification was carried out in these clones (Figure 47b and 48c). The band signifying 
positive integration can be seen amplified and this is extracted to be purified for 
sequence verification (Figure 47b and 48c). Indeed, integration in both A4CXmC and 
M1CXmC cells were confirmed on two sites 1bp apart within the correct region (Figure 
Figure 48. Validation of M1CXmC clones. (a) FACS analysis of mCherry fluorescence in two 
M1CXmC clones grown in monolayer conditions compared to the parental 786-M1A_LCB 
control cells. (b) FACS analysis of mCherry fluorescence in two M1CXmC clones grown in 
spheroid conditions compared to the parental 786-M1A_LCB control cells (c) Genomic 
amplification of the CXCR4-mCherry integration site in single-cell derived clones. Arrow 
signifies successful integration. WC, water control. GC, genomic control.  
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49). Other faded bands can be seen in the genomic amplified clones due to unspecific 
binding of primers in the genomic DNA samples. Importantly, PCR amplification of 
water controls (WC) showed no contamination as no bands were present, whilst the 
unspecific bands can be seen amplified in the genomic controls (GC) but not the bands 
signifying positive integration (Figure 47b and 48c).  
In tissue culture, CXCR4 mRNA and protein expression has been shown to 
increase when cells are grown in spheroid conditions245. As a preliminary test for the 
changes in mCherry fluorescence in relation to the changes in CXCR4 mRNA and 
protein expression, all 4 clones were grown into spheroids using an ultra-low 
attachment plates for up to 3 days. This procedure has been proven for spheroid 
formation246. Spheroids were then extracted and FACS analysed for their mCherry 
fluorescence. A4CXmC clones grown in spheroids showed 20 times greater mCherry 
fluorescence compared to the parental control and 3 times greater than that of the 
Figure 49. Sequencing of integration sites. (a) Sanger sequencing of the CXCR4-mCherry 
integration sites in A4CXmC clones. (b) Sanger sequencing of the CXCR4-mCherry 
integration sites in M1CXmC clones. UTR, untranslated region. IRES, internal ribosome 
entry site.  
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clones grown in monolayer conditions (Figure 47a). Spheroids of M1CXmC clones 
showed mCherry fluorescence of up to 14 times greater than the parental control 
(Figure 48b) while the monolayer grown clones only showed mCherry fluorescence of 
3 times greater than the control (Figure 48a). These results show that the mCherry 
reporter systems are expressing under the same promoter of the CXCR4 gene. 
 
5.3.2 Functional validation of CXCR4 reporter systems 
 The proven relationship between CXCR4 and HIF2A was put to test to validate 
the functionality of the CXCR4 reporter systems. As a direct downstream target of 
HIF2A114, CXCR4 mRNA and protein expression should be inhibited with the loss of 
HIF2A. VHL was reintroduced to degrade HIF2A proteins in these VHL-mutated clones 
in the form of a HA-VHL expressing plasmid. An empty vector (EV) plasmid was also 
transduced as a control. Relative mRNA levels and western blot analysis of A4CXmC 
clones transduced with HA-VHL clearly showed the presence of VHL mRNA and 
protein respectively (Figure 50a and 50b). This in turn corresponded with the reduction 
in HIF2A protein levels as they are targeted for degradation by VHL protein (Figure 
50b). With the reduction in HIF2A protein, CXCR4 mRNA expression was shown to 
be reduced significantly as well in the A4CXmC clones (Figure 50a). In the EV 
transduced A4CXmC clones, no VHL protein or mRNA was detected which left the 
HIF2A protein to be stabilized and thus stabilizing CXCR4 mRNA expression levels 
(Figure 50a and 50b). These results were recapitulated in the M1CXmC clones 
transduced with either HA-VHL or the EV plasmid (Figure 51a and 51b). Assessing 
effects of the changes in CXCR4 mRNA expression levels on the mCherry 
fluorescence showed an expected reduction in fluorescence in the VHL-reintroduced 
- 114 - 
 
A4CXmC and M1CXmC clones. In the A4CXmC clones transduced with HA-VHL, a 
reduction of around 5-fold can be seen in the mCherry fluorescence when compared 
to the untransduced A4CXmC controls (Figure 50c). In the VHL-reintroduced 
M1CXmC clones, a decrease in mCherry fluorescence of around 2-fold was shown 
compared to the untransduced M1CXmC controls (Figure 51c). As expected in all the 
clones transduced with the EV plasmid, no significant decrease in mCherry 
fluorescence can be seen (Figure 50c and 51c). Based on these data, it is clear that 
the mCherry is expressed together with the CXCR4 gene under its endogenous 
promoter. Furthermore, to test for the activity of the Cas9 expressed in the A4CXmC 
and M1CXmC cells, an experiment was carried out by transducing these cells with an 
Figure 50. VHL-reintroduction in A4CXmC cells. (a) Relative mRNA levels of VHL and 
CXCR4 in A4CXmC cells transduced with either VHL-expressing (HA-VHL) plasmid or an 
empty vector (EV) control plasmid. Analysis based on triplicates of technical repeats and 
single biological repeat. (b) Western blot analysis of A4CXmC1 and A4CXmC2 cells 
transduced with either HA-VHL or EV plasmids. B-actin acts as a loading control. Single 
biological repeat. (c) FACS analysis of mCherry fluorescence in A4CXmC cells transduced 
with either HA-VHL plasmid or an EV plasmid. Untransduced A4CXmC control cells serves 
as a positive control.  
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sgRNA targeting HNF1B that was shown to have a prominent effect on its mRNA 
expression level, by Emma Richardson, a student in the lab (Figure 52). All four 
CXCR4 reporter systems showed a marked decrease in the mRNA expression levels 
of HNF1B when compared to the non-targeting control transduced cells (Figure 52). 
Therefore, all four CXCR4 systems are viable for the monitoring of changes in the 
mRNA expression level of CXCR4 which would be very useful in a pooled-based 
screening concept as proven in the H2AmC systems (Chapter 4).  
 
5.4 Screening of CXCR4 mCherry system 
Figure 51. VHL-reintroduction in M1CXmC cells. (a) Relative mRNA levels of VHL and 
CXCR4 in M1CXmC cells transduced with either VHL-expressing (HA-VHL) plasmid or 
an empty vector (EV) control plasmid. Analysis based on triplicates of technical repeats 
and single biological repeat. (b) Western blot analysis of M1CXmC1 and M1CXmC2 cells 
transduced with either HA-VHL or EV plasmids. B-actin acts as a loading control. Single 
biological repeat (c) FACS analysis of mCherry fluorescence in M1CXmC cells 
transduced with either HA-VHL plasmid or an EV plasmid. Untransduced M1CXmC 
control cells serves as a positive control. 
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5.4.1 Chromatin-Modifying Regulator Library Screen 
As an accompaniment to the chromatin library screen carried out in the HIF2A 
systems, screening its known direct downstream target, CXCR4, for potential novel 
regulators would better illustrate the mechanisms by which HIF2A functions with its 
co-regulators. This will unravel the activity involved downstream of the main effector 
of ccRCC dependencies. More specifically, data obtained from these screens and the 
H2AmC screens could highlight important factors more clearly as it is known that cell-
type specific gene expression programs are governed by cell-type specific chromatin 
modifications247. It could be possible that the high mRNA expression of HIF2A seen in 
ccRCC is correlated with a ccRCC-specific chromatin modification program that 
affects both HIF2A and in general, its metastatic programme.   
 
5.4.1.1 Library screening in M1CXmC cells 
Figure 52. Cas9 activity testing in the CXCR4 reporter systems. (a) Relative mRNA levels 
of HNF1B in A4CXmC cells transduced with either a non-targeting control (CTRL) sgRNA 
plasmid or a HNF1B targeting sgRNA plasmid. (b) Relative mRNA levels of HNF1B in 
M1CXmC cells transduced with either a CTRL sgRNA plasmid or a HNF1B targeting sgRNA 
plasmid. All the data shown is a triplicate of technical repeats with single biological repeat. 
All analysis based on triplicates of technical repeats and single biological repeat. 
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5.4.1.1.1 Screening procedure 
 Despite the lack of novel regulatory factors isolated from the H2AmC screens, 
the screening procedure was highly validated. The results obtained from the H2AmC 
screens were either affected by the type of sgRNA library used or the reporter systems 
being interrogated. There is no certainty that the same outcome will be produced in 
CXCR4 systems due to the different genetic landscape in question. For these reasons, 
the screening procedure that was performed in the H2AmC systems was carried out 
on the CXCR4 systems (Figure 53).  
 The M1CXmC systems were produced from the 786-0 metastatic derivative 
ccRCC cell line, 786-M1A. With the aim of delineating the regulation behind the 
metastatic programme of ccRCC through CXCR4, the M1CXmC systems would be 
better candidates than the A498 ccRCC cell line-derived A4CXmC systems. 
Therefore, the chromatin screen focused on the M1CXmC cells. In addition, duplicates 
of each M1CXmC systems were screened for in parallel. Around 120 million cells of 
M1CXmC systems were transduced at 10% positive BFP cells to yield a MOI of around 
0.11. This gives greater than 95% of cells with single integration. Transduced cells 
Figure 53. Schematic showing the screening process with the chromatin library in 
M1CXmC systems. A pool of sgRNAs targeting chromatin factors was cloned into a 
lentiviral vector. M1CXmC cells were transduced with the virus and selected for under 
puromycin selection. This is followed by isolation of surviving cells for the lowest 10% of 
mCherry fluorescence. sgRNA enrichment assessed by high-throughput sequencing. 
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were treated with puromycin for 4 days to select around 12 million cells which maintain 
>1000X of sgRNA representation from the chromatin library. This representation is 
chosen as the sequencing of the plasmid library showed around 1000x difference 
between the lowest and highest represented sgRNAs. Furthermore, it has been shown 
to be a faithful method to ensure adequate representation of the library with minimal 
noise for the screen234,236. Isolated cells from each M1CXmC systems were then 
grown in three batches, one as an unsorted control and the other two as duplicates of 
sorted samples, all of which were seeded and maintained at 12 million cells. Three 
weeks post infection, the bottom 10% of the transduced M1CXmC cells were sorted 
for. These samples were pelleted along with the unsorted controls and followed by 
purification steps before submitting for deep sequencing (Figure 53). Purified samples 
Figure 54.  Validation of chromatin library screening samples. (a) PCR amplification of the 
guide sequence (274bp) from each sample along with their respective water control (WC). 
(b) Sequencing of the pooled sample showing multiple peaks signifying multiple sgRNA 
sequences. 
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were checked for PCR amplified bands of the guide sequence that is 274bp and 
sequencing of pooled samples came back positive with multiple peaks that represents 
multiple sgRNAs from the library (Figure 54). 
 
5.4.1.1.2 Analysis of screening 
 Sequencing data was aligned by Sakari Vanharanta with BowTie sequence 
alignment software and normalised counts of each sgRNA per million reads were 
produced for every M1CXmC samples. The average normalised sgRNA counts of 
duplicates of sorted samples for each M1CXmC system were calculated. A plot of 
average normalised sgRNA counts for M1CXmC1 against M1CXmC2 system was 
produced with a good Pearson Correlation Coefficient (PCC) of 0.6982 (Figure 55). 
Fold change enrichment scores in each M1CXmC system were calculated for each 
sgRNA when the counts per million reads of the sorted samples were compared to 
those of the unsorted controls. Focusing on the fold change enrichment of sgRNAs 
Figure 55. Correlation plot of the normalized sgRNA counts per million reads in unsorted 
M1CXmC1 and M1CXmC2 cells. PCC, Pearson’s Correlation Coefficient. 
PCC: 
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targeting HIF2A, the positive control of the screen, poor PCC values can be seen 
(Figure 56). Since duplicate results of sorted samples for each M1CXmC systems 
were available, a number of analysis strategies were applied to plot fold change 
enrichment scores of HIF2A between the two systems.  First strategy was to use the 
average fold change enrichment scores of sample 1 (S1) and sample 2 (S2) for each 
M1CXmC system and plot them against one another (Figure 56a). The following 
strategies involved combinations of S1 only from both systems (Figure 56b), S2 only 
from both system (Figure 56c), S1 from M1CXmC1 with S2 from M1CXmC2 (Figure 
56d), and lastly S2 from M1CXmC1 with S1 from M1CXmC2 (Figure 56e). All of these 
analysis strategies yielded PCC values of less than 0.3 for HIF2A sgRNA fold change 
enrichment scores between the two systems. Furthermore, manual observation of the 
Figure 56. Correlation plots of fold enrichment of HIF2A sgRNAs in M1CXmC1 and 
M1CXmC2 cells under five different analysis strategies. (a) Fold enrichment scores were 
calculated using an average of sample 1 (S1) and sample 2 (S2) of each M1CXmC system. 
(b) Fold enrichment scores from S1 only. (c) Fold enrichment scores from S2 only. (d) Fold 
enrichment scores from S1 of M1CXmC1 and S2 of M1CXmC2. (e) Fold enrichment scores 
from S2 of M1CXmC1 and S1 of M1CXmC2. 
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sgRNA enrichment scores for HIF2A sgRNAs were not as drastic as those observed 
in the analysis of the H2AmC systems. 
 To further confirm if the screen was a success or not, the median of the sgRNA 
enrichment scores for each gene was calculated in each system based on the five 
analysis strategies mentioned earlier. Firstly, the median of all sgRNA enrichment 
scores was considered for each gene (Figure 57). Plots of these scores were produced 
between the two systems for each analysis strategy. All five analysis strategies 
showed most genes were clustered within the centre of the plot with little to no obvious 
enriched gene in both systems (Figure 57). Importantly, HIF2A did not come out 
anywhere near the top most enriched gene. Another method of calculation was also 
applied whereby only the top four scoring sgRNAs were considered in the calculation 
Figure 57. Median gene enrichment scores (z-scores) of all sgRNAs of each gene in the 
M1CXmC1 and M1CXmC2 cells using five different analysis strategies. (a) Median gene 
enrichment scores were calculated using an average of sample 1 (S1) and sample 2 (S2) 
of each M1CXmC system. (b) Median gene enrichment scores from S1 only. (c) Median 
gene enrichment scores from S2 only. (d) Median gene enrichment scores from S1 of 
M1CXmC1 and S2 of M1CXmC2. (e) Median gene enrichment scores from S2 of 
M1CXmC1 and S1 of M1CXmC2. 
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of their respective median gene enrichment scores. Plots of these enrichment scores 
were produced between the two systems for all five analysis strategies (Figure 58). 
The top four median gene enrichment scores showed more dispersed enriched genes 
than the median all analysis but most were still clustered in the middle with low 
enrichment scores (Figure 58). In this analysis, HIF2A still did not come up as one of 
the top-most hits. Manual analysis of the top 75 sgRNA enrichment scores where two 
non-targeting controls appear showed no presence of sgRNAs against HIF2A. 
 
5.5 Testing Cas9 activity in A4CXmC and M1CXmC systems 
Figure 58. Median gene enrichment scores (z-scores) of the top four scoring sgRNAs of 
each gene in the M1CXmC1 and M1CXmC2 cells using five different analysis strategies. 
(a) Median gene enrichment scores were calculated using an average of sample 1 (S1) 
and sample 2 (S2) of each M1CXmC system. (b) Median gene enrichment scores from S1 
only. (c) Median gene enrichment scores from S2 only. (d) Median gene enrichment scores 
from S1 of M1CXmC1 and S2 of M1CXmC2. (e) Median gene enrichment scores from S2 
of M1CXmC1 and S1 of M1CXmC2. 
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 Despite the validation steps taken to test the viability of the CXCR4 systems, 
the screens came out inconclusive and invalidated. One aspect of the CXCR4 systems 
that is different to that of the H2AmC systems apart from method of integration is that 
the cell lines in use to produce the clones differ in their Cas9 activity. The H2AmC 
systems were produced from clones made out of cell lines that do not constitutively 
express Cas9 and therefore Cas9 was integrated into the clones at a later stage post-
Figure 59. Cas9-based sgRNA targeting in A4CXmC cells and M1CXmC cells. (a) FACS 
analysis of mCherry fluorescence in A4CXmC cells transduced with sgRNAs against HIF2A 
(sgEPAS1-1, sgEPAS1-5) and a non-targeting control (CTRL). (b) FACS analysis of 
mCherry fluorescence in M1CXmC cells transduced with sgRNAs against HIF2A 
(sgEPAS1-1, sgEPAS1-5) and a non-targeting control (CTRL). Parental control and 
M1CXmC clone control act as negative and positive controls, respectively. 
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validation experiments and prior to the start of the screenings. When the Cas9-
expressing H2AmC systems were produced, the strongest expressing clones were 
also selected for the screens.  On the other hand, the CXCR4 reporter systems were 
produced using Cas9-expressing cell lines and the clones produced were used 
throughout the validation steps followed by the screens. In hindsight, there may have 
been a difference in the activity level of Cas9 between the H2AmC systems and the 
CXCR4 reporter systems which may explain the difference in the success of the 
screens. This occurred despite the validation experiments carried out on all four 
CXCR4 reporter systems for its Cas9 activity using an sgRNA against the HNF1B 
gene (Figure 52). The results obtained from this analysis showed good downregulation 
of HNF1B mRNA expression levels but this may not be representative of average 
sgRNA activity in a library context (Figure 52).  
 The same experiment that involved the transduction of BFP-expressing 
plasmids bearing single sgRNAs targeting HIF2A (CTRL, sgEPAS1-1, sgEPAS1-5) in 
Cas9-expressing H2AmC clones were carried out in the CXCR4 systems. A4CXmC 
cells transduced with sgEPAS1-1 or sgEPAS1-5 showed no significant shift in the 
mCherry fluorescence when compared to the CTRL transduced A4CXmC cells (Figure 
59a). This was only recapitulated in the sgEPAS1-1 transduced M1CXmC1 cells when 
compared to the CTRL transduced M1CXmC1 cells but not in the sgEPAS1-1 
transduced M1CXmC2 cells (Figure 59b). Both M1CXmC cells transduced with 
sgEPAS1-5 on the other hand showed a significant reduction in the mCherry 
fluorescence when compared to the CTRL-transduced cells (Figure 59b). Both 
sgEPAS1-1 and sgEPAS1-5 have been shown previously in the H2AmC systems to 
be two of the strongest acting sgRNAs targeting the mRNA expression of HIF2A and 
both showed a significant reduction in the mCherry fluorescence of the transduced 
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H2AmC cells (Figure 27). The inconsistent effect seen in the CXCR4 reporter systems 
would seem to point towards the strength of their Cas9 expression that would affect 
the activity of the sgRNAs. 
 
5.6 Conclusion 
 This chapter highlights another way of developing endogenous reporter 
systems by utilising the NHEJ repair pathway following CRISPR-Cas9 double 
stranded break. A procedure called homology-independent targeted integration (HITI) 
was carried out that employed a minicircle plasmid as a template to integrate an 
mCherry gene into the endogenous locus of CXCR4 gene, a known downstream target 
of HIF2A248. Two ccRCC cell lines were amenable to such procedure producing two 
reporter clones each in the 786-M1A and A498 cells (M1CXmC and A4CXmC 
systems). The M1CXmC systems were utilised in a high-throughput functional 
screening interrogating the chromatin landscape of CXCR4. The outcome of the 
screen was not a success that could be attributed to the Cas9-expression levels in the 
CXCR4 reporter systems. Nonetheless, these CXCR4 reporter systems holds the 
potential of visualizing the activity of HIF2A and its regulatory mechanism behind the 
metastatic potential of ccRCC progression.  
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Chapter 6: Discussion 
6.1 Introduction 
 This thesis reports the development of endogenous reporter systems 
monitoring HIF2A mRNA expression and CXCR4 mRNA expression in ccRCC cells 
and their application in high-throughput functional CRISPR-Cas9-based loss-of-
function screening. Development of ccRCC is mediated by HIF2A and this has been 
shown to be a validated therapeutic target152–154. Additionally, different levels of HIF2A 
mRNA and protein expression and acquired mutation in the HIF2A complex have been 
attributed to varying sensitivity of ccRCC cells to HIF2A inhibition153. CXCR4 is a well-
known direct downstream target of HIF2A and its high mRNA and protein expression 
has been documented in a number of cancer types as well as contributing to the 
initiation and progression of cancer metastasis114,131,133–135,137,139. Yet, the 
mechanisms that regulate the high levels of HIF2A mRNA expression that is specific 
to ccRCC along with subsequent regulatory factors involved in its downstream gene 
expression program are incompletely understood.  
 Transcriptional deregulation in cancer has been shown to involve a number of 
aberrantly expressed transcription factors (TF), such as MYC, that are part of a much 
larger network of TFs promoting a myriad of gene expression programs to sustain their 
own survival235,249. Here, the transcription factor network involved in the high mRNA 
expression level of HIF2A in ccRCC was explored. Screening with the H2AmC 
systems with a TF library produced a strong signal for HIF2A, the positive control. 
Other top scoring TFs were statistically insignificant whereas HIF2A was the sole 
significant hit. Even with no isolation of novel regulatory factors of HIF2A mRNA 
expression, this initial screen confirms technical validity of our approach. 
- 127 - 
 
 Another aspect of investigation relating to transcriptional deregulation is the 
chromatin landscape of the gene expression program of HIF2A. Recent evidence has 
shown that the expression of oncogenic drivers can be dependent on single chromatin 
modifiers such as Brd4250. Here the chromatin factor dependencies of HIF2A mRNA 
expression was investigated using the H2AmC systems. Despite another strong signal 
for the positive control of the screen, HIF2A, little evidence was found for the existence 
of individual chromatin factors that would be essential for HIF2A mRNA expression in 
ccRCC. Nevertheless, this screen further validates the screening approach with the 
application of a different form of sgRNA library. In depth analysis of the essential genes 
that was included in this screen also showed that their sgRNAs dropped out the most 
when compared to the original plasmid library, thus highlighting that the screen is 
functional. Taking the results obtained from both TF and chromatin screens with the 
H2AmC systems, redundancy within the HIF2A gene regulatory machinery might 
explain the inexistence of a master regulatory factor.  
 Even with the difficulty of highlighting regulatory factors of HIF2A mRNA 
expression in ccRCC, its activity and the respective components involved in HIF2A’s 
downstream gene expression program was investigated in the CXCR4 reporter 
systems. Chromatin factor dependencies of CXCR4 was inspected in the M1CXmC 
systems due to the pronounce nature of the HIF2A signal isolated in the chromatin 
library screen of H2AmC systems. Inconclusive results were obtained from this screen 
as the positive control, HIF2A, did not come out as one of the top scoring factors. This 
may be attributed to the strength of the Cas9 expression in the CXCR4 reporter 
systems that could result in variable and lower specificity of sgRNA targeting.  
 
- 128 - 
 
6.2 Generation of endogenous HIF2A fluorescent reporter systems through CRISPR-
Cas9-based HDR knock-in method in ccRCC cells. 
 Genome editing through CRISPR-Cas9 has opened up unprecedented 
possibilities for biological research. However, the general efficiency of CRISPR-Cas9 
gene editing across the many possible biological contexts remains to be established. 
Different forms of plasmid templates have been generated for homology-directed 
repair (HDR)-based transgene knock-in and the type of template chosen affects 
integration rates197. The length of the homology arms used depends on the size of 
transgene to be integrated into the genome. Plasmid donors of at least 1-2 kb of total 
homology is usually used for large sequence changes197,251. However, reporter genes 
have also been shown to be integrated using plasmid donors with homology arms of 
500bp or less252,253. Moreover, it was observed that linearized double-stranded 
plasmid templates yielded a higher percentage of integration than an uncut plasmid 
donor template197.  
As an initial approach to constructing an HDR plasmid template involving 
multiple cloning steps, only the most used design methods were adhered to in this 
project. Greater than 1kb of homology arms were used to ensure integration and a 
selection marker was included for greater confidence in the isolation of positive clones. 
Nevertheless, a Cre-lox system254 was not included in the design of the HDR template 
which may have some implication on the efficiency of the clones. The presence of the 
hygromycin resistant gene within the endogenous gene may have impaired the 
endogenous gene expression in some clones which would explain the low percentage 
of positive mCherry clones despite having gone through a selection process.  
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 Further to the design of the template, the degree to which an intact HDR 
pathway is required for HDR-targeted gene editing in cancer cell lines remains unclear. 
Mutations in the histone methyltransferase SETD2 is common in ccRCC255. SETD2 is 
an enzyme that trimethylates histone H3 lysine 36 (H3K36me3) for ATM activation 
upon DNA double-stranded breaks (DSBs)256. By promoting the formation of RAD51 
presynaptic filaments, SETD2 is also necessary for homologous recombination repair 
of DSBs257. Indeed, SETD2-mutant ccRCC cells displayed impaired DNA damage 
signalling256. This observation suggests that one of the requirements for ccRCC 
development may be defects in some DNA repair pathways, possibly hindering the 
efficiency of HDR-mediated gene editing in ccRCC cells. The results showed that at 
least some ccRCC cell lines are amenable for HDR-based gene editing, but 
unfortunately with a lower efficiency than what has been reported in some other 
systems201. Some ccRCC cell lines tested also failed to integrate the fluorescent 
reporter construct. 
 Alternative strategies to increase efficiency include the use of an additional drug 
treatment, RS-1, that has been shown to enhance the homologous recombination 
protein RAD51258. This can be used in addition to the DNA ligase IV inhibitor, SCR7231 
that was already in use for the production of the HIF2A reporter clones. HDR efficiency 
could also be improved by synchronizing the cells by arresting them in the G2/M phase 
of the cell cycle using compounds such as ABT-751 and Nocodazole259. 
 
6.3 Generation of endogenous CXCR4 fluorescent reporter systems through CRISPR-
Cas9-based NHEJ knock in method in ccRCC cells.  
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 Newer methods of CRISPR-Cas9 integration were applied that challenged the 
need for an HDR-based repair for precise transgene knock-in. In fact, the DNA 
damage repair pathway is dominated more by the NHEJ pathway compared to the 
HDR pathway202. This could also be one explanation as to the generally low integration 
rates observed in HDR-based CRISPR-Cas9 knock-ins203,204. Even with the 
knowledge of insertion and deletion (indels) formations as a result of an NHEJ-based 
DNA repair pathway, studies have shown that a template without any homology arms 
could result in a higher percentage of transgene integration203,204. Homology-
independent targeted integration (HITI)-mediated genome editing using a minicircle 
plasmid template with no homology arms showed around 50% positive integration with 
no mutations of reporter construct in HEK293 cells which was a far greater knock-in 
efficiency compared to the use of HDR templates204. In my project, despite roughly 
similar percentages of positive clones isolated from either HDR or NHEJ-based 
reporter integration, the use of a minicircle as a template did not comprise of a drug 
selection marker whilst the HDR plasmid template did. This was decided against due 
to the high efficiency level recorded in the HITI method of integration204, thus hoping 
for a much better chance at isolating positive clones. Moreover, the omission of a 
selection step reduced the time frame of reporter clone production.  
 Additional steps could be taken to further improve the generation of these 
reporter systems with the HITI method. These include the addition of a selection 
marker within the minicircle plasmid template that is also flanked with a loxP sequence 
cut site on each side. The selection step would add another level of confidence in the 
isolation of only the positively integrated clones prior to single cell sorting. 
Furthermore, it will provide more fluorescent clones to choose from and the integrated 
selection marker could easily be removed post clonal isolation to avoid possible 
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hindrance to the expression of the mCherry gene. Based on the sequencing results of 
the CXCR4 clones isolated from the HITI method, integration of fluorescent reporters 
was precise. This means that instead of focusing on the 3’ UTR of the CXCR4 gene 
for integration, the mCherry construct could have been targeted within the exon of the 
gene just upstream of the stop codon. Indeed, a PAM sequence is available on this 
site. This would obviate the need for a large IRES sequence and replace it with a 
smaller and efficient T2A self-cleaving peptide as carried out for the H2AmC systems 
to ensure production of equally separated amounts of both endogenous and reporter 
proteins228,229.  
 
6.4 Endogenous H2AmC fluorescent reporter systems for high-throughput genetic 
interrogation to delineate the regulatory mechanism of HIF2A mRNA expression in 
ccRCC.  
 The strong signal for HIF2A in the genetic screens carried out in the H2AmC 
systems to interrogate transcription factor (TF) regulators and chromatin regulators 
provided a strong technical validation for the systems and the screening approach. 
Yet, it remains possible that the systems are not sensitive enough to identify factors 
that only subtly affect HIF2A mRNA expression. In fact, some regulatory factors may 
not have been efficiently targeted or excluded due to technical reasons. It is possible 
that some aspects of the screening procedure may have affected the efficiency of the 
screening. 
Firstly, in the TF screen of the H2AmC systems, the two-sorting approach 
involved the re-plating of the initial sorted population of cells followed by a second 
sorting step. Besides the added length to the screen, this procedure introduced a 
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number of stresses to the cells that could be toxic thus resulting in the loss of 
potentially important sgRNAs due to cell death. Moreover, the TF library was cloned 
into a backbone that consists of a hygromycin selection marker that selects for positive 
cells over a longer period of time than other selection markers. Due to the TF library 
having similar selection marker as the integrated reporter construct in the H2AmC 
cells, selection for positively transduced cells were not carried out. Instead, positive 
cells were isolated only prior to sorting of the lowest mCherry population. This means 
that the H2AmC cells that were transduced and left to grow would have a mix of cells 
with and without sgRNA integration. Therefore, when it comes to sorting there would 
potentially be less cells with sgRNA integration to be isolated as samples. Though this 
might not necessarily affect the outcome of the screen, having a large number of cells 
as samples is preferred to ensure sgRNA representation is not affected throughout the 
screen. This could easily be prevented by interrogating the H2AmC systems with a 
sgRNA library carrying a different selection marker, preferably one that isolates 
positive cells faster to avoid further toxicity to the cells.  
 The chromatin factor screen in the H2AmC systems produced a more profound 
signal for the HIF2A positive control compared to the TF screen. Some aspects of this 
particular screen that differ to the TF screen includes the generation of the library in a 
newer form of backbone (pKLV2-U6gRNA5(BbsI)-PGKpuro2ABFP-W) (Addgene 
#67974)179. This new plasmid backbone has been shown to have a better performance 
than its predecessor (pKLV-U6gRNA(BbsI)-PGKpuro2ABFP) (Addgene #50946)208. In 
addition, this new plasmid carried a puromycin resistant gene that selects for positive 
clones at a much greater rate in ccRCC cells compared to hygromycin selection. Apart 
from that, the second sorting step applied in the TF screen that isolates the bottom 1% 
of the original mCherry population transduced with the library was disregarded in the 
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chromatin factor screen of H2AmC systems. Instead, cells were collected straight after 
the first sorting step that isolated the bottom 10% of the mCherry population, which 
was then prepared for deep sequencing. Ultimately, these changes increased the 
efficiency of the sorting procedure that included reduced time and stronger sgRNA-
based interrogation of the regulatory factors involved. Nevertheless, only HIF2A came 
out as the sole significant hit with no other novel regulators isolated despite the 
increase from 7 sgRNAs to 9 sgRNAs per gene in the chromatin library used for gene 
interrogation when compared to the TF screen. This repeated observation highlights 
the strength of these H2AmC systems to isolate the strongest factors affecting HIF2A 
mRNA expression. Importantly, this proposes an explanation to the difficulty in 
understanding and targeting the regulatory machinery of HIF2A mRNA expression as 
multiple factors could be involved that works together to sustain the high mRNA 
expression levels rather than a single master regulatory factor.  
 Different strategies for the screenings in the H2AmC systems should include 
the use of a more efficient selection process to reduce the time spent by transduced 
cells under toxic conditions. Further consideration has to be made with the total 
screening time for future screens to ensure minimal passaging with the consideration 
of the half-lives of the endogenous HIF2A protein and mCherry that was expressed 
prior to library transduction. As an alternative to the sorting method, the entire mCherry 
population can be sorted into different sets of bins based on their mCherry 
fluorescence intensity260. For example, instead of only isolating the lowest 10% of the 
mCherry population, a top and middle population could also be isolated without any 
overlapping between the three sorted populations. Sorting methods such as this has 
been successfully applied to discover important regulatory elements from screens260. 
Essentially it gives more samples to work with and hopefully increases the sensitivity 
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of these systems to isolate more mildly affecting regulatory factors of HIF2A mRNA 
expression. 
Besides technical alternatives for the screening process, the results obtained 
from the H2AmC screens point to the need for simultaneous targeting of multiple 
chromatin factors for efficient inhibition of HIF2A mRNA expression. Combinatorial 
CRISPR-Cas9 screens would therefore represent an interesting avenue forward261. 
More recently, combinatorial CRISPR screening was used to elucidate gene 
essentiality and interactions in the cancer metabolic network262. In addition, a versatile 
platform of combinatorial genetics en masse (CombiGEM)-CRISPR can rapidly 
assemble barcoded combinatorial genetic libraries that can be tracked with high-
throughput sequencing263. Targeting other gene sets or performing genome-wide 
screens could also give new insight into HIF2A regulation. The endogenous 
transcriptional reporters, H2AmC2 and H2AmC3, developed herein could also be 
suitable for unbiased functional analysis of gene regulatory element function through 
a tiling-based sgRNA library screen264,265 interrogating the enhancers of HIF2A.  
 
6.5 Application of endogenous CXCR4 reporter systems for high-throughput genetic 
screening. 
 The outcome of the screens carried out in M1CXmC systems may be due to 
insufficient levels of Cas9 expression in these cells. Cas9-expressing ccRCC cells that 
originated from pooled sorting of Cas9-transduced cells were used for the production 
of the CXCR4 reporter clones. The idea behind this was to avoid the need to 
reintroduce Cas9 into the clones and isolate subclones prior to screening compared 
to those that were generated for HIF2A, thus streamlining the production process. 
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What was not anticipated was that despite testing the functionality of Cas9 in these 
cells using an sgRNA known to have a good reduction on mRNA expression level, this 
validation experiment may not be the right representative of the average sgRNA 
targeting activity within the sgRNA pool library. Furthermore, these Cas9-expressing 
CXCR4 reporter systems possess variable Cas9-expression levels as they were not 
produced from single cell sorted Cas9 positive parental cells.   
Alternatively, subclones of the Cas9-expressing CXCR4 systems should be 
produced by transducing them with another Cas9-expressing plasmid to isolate the 
highest expressing Cas9 subclones as similarly done for the production of H2AmC 
systems. These subclones should then be verified for their ability to isolate regulatory 
factors of CXCR4 mRNA expression by targeting the HIF2A gene before its application 
in high-throughput screens. Lastly, the production of future reporter systems with the 
HITI method should be carried out using original ccRCC cell lines. This would also 
enable another validation step to be carried out with the new clones through dCas9 
targeting similar to those carried out on the H2AmC systems, thus adding more 
certainty of its usefulness in a pooled genetic screening.  
 
6.6 Conclusion 
 To summarise, experimental systems have been developed and validated for 
the identification of factors that regulate HIF2A mRNA expression in ccRCC cells. It 
was demonstrated that these systems are compatible with pooled genetic screens. In 
addition, experimental systems have also been developed and validated for the 
identification of factors that support CXCR4 mRNA expression to molecularly 
interrogate the activity of HIF2A in ccRCC cells. Nevertheless, additional steps have 
- 136 - 
 
to be taken for the CXCR4 reporter systems to be compatible with pooled genetic 
screens. With the optimisation of the targeting library and approach, these systems 
could potentially illustrate the regulatory landscape surrounding HIF2A as the main 
effector of ccRCC tumorigenesis. Furthermore, in combination with microscopy they 
may also be compatible with small molecule screens in an arrayed format. More 
generally, this project acts as a proof-of-concept for similar systems to be generated 
to identify transcriptional dependencies in other cancer contexts as well.    
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